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1. INTRODUCTION 
 
           The goal of any drug delivery system is to provide a therapeutic amount of drug 
to the proper site of action in the body, to achieve promptly and then maintain the desired 
drug concentration. 
 
           Conventional drug delivery system achieves as well as maintains the drug 
concentration within the therapeutically effective range needed for treatment only when 
taken several times a day. These results in a significant fluctuation in drug level, dose 
related side effects and poor patient compliance [1]. These problems were totally alleviated 
due to the advent of Novel drug delivery systems (NDDS) in the domain of drug delivery. 
 
          Novel drug delivery system has two important prerequisites one was controlled drug 
delivery and another was the targeted drug delivery, it means that delivering the drug at a 
rate directed by the needs of the body, over the period of treatment and exactly nearer to the 
site of action. 
 
Controlled & Novel delivery envisages optimized drug in the sense that the 
therapeutic efficacy of a drug is optimized, which also implies nil or minimum side effects. 
It is expected that the 21st century would witness great changes in the area of drug delivery. 
The products may be more potent as well as safer.  
 
Target specific dosage delivery is likely to overcome much of the criticism of 
conventional dosage forms. The cumulative outcome could be summarized as optimized 
drug delivery that encompasses greater potency & greater effectiveness, lesser side effects 
and toxicity, better stability, low cost hence greater accessibility, ease of administration and 
best patient compliance [2]. 
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1.1 Targeted drug delivery system [3, 4]  
 
Drug targeting can be defined as the ability to target a therapeutic agent specifically to 
desired site of action with little or no interaction with non target tissue thus minimizes the 
side effects and increases the therapeutic index of drugs.  
Paul Ehrlich described the targeting of the drugs to the desired site of action in the 
body as “magic bullet”. 
The efforts to improve drug effectiveness in therapeutics have been assisted by 
parallel developments in molecular and cell biology.  Such developments supported the 
successful generation of target oriented drug delivery systems. 
 
Targeted drug delivery systems were acceptable under following conditions, 
i. Drugs with low specificity and low therapeutic index. 
ii. Stability of the drug is poor. 
iii. Drugs which were having short biological half life and also large 
volume of distribution. 
 
1.1.1 Levels of drug targeting: 
 The various levels of targeting the drug to the site of action were as follows: 
1. Passive targeting 
2. Inverse targeting 
3. Active targeting  
4. Dual targeting  
5. Double targeting and 
6. Combination targeting. 
 
Passive targeting 
Drug delivery Systems that were targeting the systemic circulation were generally 
known as “passive” delivery systems. In this type of targeting, drug delivery system were 
taken up by Reticuloendothelial cells occurs in the physiological fluids and then accumulate 
in the spleen and liver and they become the targeting agents for the delivery to those 
compartments.  
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Inverse targeting 
Inverse targeting was based on principle to avoid the passive uptake of particulate 
carriers by RES. This was the reversion of passive targeting and hence the process was 
known as inverse targeting. The strategies that were used to overcome the defence 
mechanism of RES or to achieve inverse targeting modification of the size, surface charge, 
composition and hydrophilicity of carriers were modified. And also to suppress the function 
of RES macromolecules like Dextran sulphate were used for RES blockade and leads to the 
impairment of host defence system.  
Active targeting 
The targeting of the drugs to the specific sites in the body by forming the drug-carrier 
complexes by the use of ligands to increase receptor mediated, specific delivery of drug (s) 
was known as active targeting. 
 
 
Dual targeting  
The dual targeting has offers the increased therapeutic efficacy by targeting drug 
carrier molecules, which have same beneficial therapeutic effects. These types of drug 
conjugates have synergistic effect in drug delivery. 
Double targeting 
Double targeting was a type of targeting for drug delivery systems with the 
combination made between spatial control and temporal control of drug delivery.  
Combination targeting 
Combination targeting was used for the site-specific delivery of peptide based drugs. 
These systems were equipped with carriers and polymers for a specific approach of targeting 
the drug to the site of actions.  
1.1.2 Limitations of Targeted drug delivery: 
The problems a s s o c i a t e d  w i t h  drug targeting strategies were as follows 
• Clearance of targeting systems was rapid for especially carriers of 
antibody targeting. 
• Immune reactions against carrier systems. 
• Tissue heterogenecity of targeting system was reported. 
• Localizations of drug targeted systems into tumor cells were less. 
• Diffusion and distribution of released drug leads to no-specific 
accumulation of drug in other than target site. 
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1.1.3 Carriers used in targeted drug delivery system: 
 Carriers were required for the transportation of the loaded active moieties to the 
desired site of action or nearer to the target. 
   An ideal carrier engineered as targetable device should have following features: 
• They should be able to cross membrane barriers in the body. 
• They must be recognized and selectively uptake by the target cells. 
• The drug and carrier should be stable in physiological fluids. 
•  They should be non-antigenic and biodegradable after uptake and release of the 
active moiety. 
Several carriers were used for targeted delivery were classified based on the nature of their 
origin as follows 
• Endogenous  (low & high density lipoproteins) 
• Exogenous  (Biodegradable polymeric drug carriers) 
 
                  Table 1: Carrier systems used for Targeted Drug Delivery 
S.No Type of carrier Example 
1 
 
Colloidal 
Carriers 
a) Vesicular systems 
 Niosomes, Liposomes.  
b) Microparticulate systems 
Microparticles, Nanoparticles, Magnetic Microspheres, 
Nanocapsules. 
2 Cellular Carriers Resealed erythrocytes, antibodies  
3 
     Micellar  
delivery systems 
Micelles, mixed micelles and polymeric micelles 
5 
Macro 
molecular  
carriers 
a) Proteins, glycoproteins, artificial viral   envelopes. 
b) Glycosylated polymers. 
c) Mabs, antibody enzyme complex. 
d) Toxins, conjugates. 
e) Lectins and polysaccharides. 
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1.2 NANOPARTICLE BASED TARGETED DRUG DELIVERY [5] 
 
Nanoparticles are one of the novel colloidal drug delivery systems  have the 
properties of controlled drug delivery as well as site specific delivery. Nanoparticles are the 
sub-nanosized colloidal carriers whose particle size ranges from 10-1000nm. These are made 
of non-biodegradable and biodegradable polymers. 
The polymeric nanoparticles were able to carry the active moieties by entrapping in 
their polymer matrices as particulates or adsorbed on to the surface of particles by physical or 
chemically adsorption. The drugs may be added during preparation of nanoparticles or to the 
previously prepared nanoparticles. 
 
Advantages of polymeric nanoparticles 
y They release the drug at a controlled rate and targeted drug release. 
y They have the ability in drug utilization by decreasing the initial drug loading.  
y They will provide better convenience and improved patient compliance. 
y They decrease the toxicity and occurrence of adverse reactions associated with 
conventional drug delivery systems.  
y The polymeric nanoparticles can be freeze-dried and obtained as dry powder form.  
y They were nontoxic, biodegradable, biocompatible and relatively stable. 
Types of nanoparticles [6] 
                  There were two types of nanoparticles 
• Nanospheres  
• Nanocapsules and 
• Nanomicelles 
Nanospheres : These  were solid core Spherical particulates which are nanometre in size range in 
which drug is embedded within the matrix or adsorbed on to the surface. 
Nanocapsules : These were the vesicular systems in which drug is essentially encapsulated 
within the central volume surrounded by an embryonic continuous polymeric stealth. 
Nanomicelles: These were the micellar delivery systems consists of inner hydrophobic core with 
entrapped drug and outer hydrophilic shell made from amphiphilic block copolymers with size 
range of 10 to 200 nm. 
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Types of polymers used for Preparation of Polymeric Nanoparticles[7] 
Polymers used for preparation of nanoparticles were of two types 
1. Natural hydrophilic polymers  
These were amphiphilic macromolecules obtained from natural sources like Proteins 
(Albumin, Gelatin) and polysaccharides (Alginates or Agarose). 
Disadvantage with natural polymers were antigenicity and conditional biodegradability 
2. Synthetic hydrophobic polymers  
These hydrophobic polymers were synthesized chemically. These polymers were 
investigated for their biomedical applications and consequently their safety and biodegradation 
patterns. 
These polymers were either pre-polymerized or synthesized during nanoparticle 
preparation. 
1. Pre-polymerized polymers were Poly (ε-caprolactone) , Poly (lactic acid) and Poly 
(lactide-co-glycolide) 
2. Polymers that were prepared during preparation of nanoparticles were Poly 
(butylcyanoacrylates), Poly hexylcyanoacrylate andPoly methyl (methacrylate)  
 
1.3 PREPARATION OF NANOPARTICLES [8]: 
Nanoparticles were prepared by many methods. The choice of the method of 
preparation depends on the solubility characteristics of the incorporating drugs and type of 
the raw materials that were going to be used in the Nanoparticle formulations. 
Nanoparticles were mainly prepared by the two types of processes.   
              They were 
1.  Dispersion of the preformed polymers along with active moiety. 
2.  Polymerization of monomer. 
For dispersion of the preformed polymers, several methods have been used to prepare 
polymeric nanoparticles such as  
 
•  Emulsion Solvent evaporation method. 
•  Nanoprecipitation method  
•  Dialysis method  and 
•  Supercritical fluid spraying method  
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Emulsion Solvent evaporation method: 
Single Emulsion evaporation method was the most commonly used method to load 
the hydrophobic drugs into polymeric nanoparticles. In this method, an organic mixture of 
polymer and drug was emulsified in an aqueous solution with surfactant or stabilizer to make 
an oil-in-water emulsion. The nanosized emulsion droplets were usually induced by 
homogenization. After that, organic solvent used in the preparation was evaporated by rotary 
vaccum evaporator and nanoparticles were collected by centrifugation and filtration methods. 
Double emulsion solvent evaporation method was a multiple emulsion method or 
modified method of single emulsion method which encapsulates the water soluble drugs. 
In this method an aqueous solution of the water soluble compound was first 
emulsified into an organic solution of polymer to form primary water-in-oil (w/o) emulsion. 
And this primary w/o emulsion was then poured into a large volume of water with stabilizer 
to form multiple emulsions.  
Nanoprecipitation method:  
              Nanoprecipitation was also known as interfacial deposition method or emulsification 
diffusion method.  
In this method drug and polymer were dissolved into water-miscible solvent such as 
acetone. This organ solution was added drop wise to the aqueous phase having a stabilizer or 
surfactant which sterically stabilised the formed nanoparticles. In the nanoprecipitation 
method, an interfacial turbulence will be created from the spontaneous diffusion of water-
soluble solvent to water, leading to the formation of nanoparticles. 
Dialysis method: 
Dialysis method was used for preparing stabilizer free nanoparticulate system. A 
stabilizer free nanoparticulate system was not only has the advantages of ease of preparation 
but also preventing the possible side effects of emulsifier. 
In this method drug and polymer were first dissolved in water-miscible solvent such 
as DMF or THF. Then solution was transferred into a dialysis membrane with certain 
molecular weight cut off and dialysis was performed against large volume of distilled water 
for about two days to remove free drug and organic solvent. The formed nanoparticles were 
separated by centrifugation or filtration methods. 
 Supercritical fluid spraying method:  
Supercritical fluid spraying method was a technique used for preparation of the 
nanoparticles without the use of any toxic organic solvent and stabilizer.  
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In this method the drug and polymer were solubilised in a supercritical fluid and then 
the solution was expanded through a nozzle. The supercritical fluid will undergo evaporation 
during spraying process and the drug solute will eventually precipitate into smaller 
nanoparticles. 
 Polymerization method  
             In this method the nanoparticles were prepared from monomers by poly-condensation 
reactions. Polymerization includes emulsion polymerization and interfacial polymerization. 
  Emulsion polymerization was developed into a chain of polymers from single 
monomers which was initiated by radical formation. The residual monomers were removed 
by filtration. The drug was incorporated on to the surface of nanoparticles by adsorption.  
For interfacial polymerization, monomer contained aqueous phase and organic phase 
were brought together by mechanical force. Drug was dissolved in the polymerization 
medium either before the addition of monomer or at the end of the polymerization reaction 
and finally, nanoparticles was recovered by ultracentrifugation method. 
1.4 EVALUATION OF NANOPARTICLES: 
 The nanoparticles were evaluated for various parameters they were: 
1. Percentage yield 
2. Drug loading 
3. Entrapment efficiency 
4. Size and morphology 
5. In vitro drug release studies 
6. Stability testing 
Percentage Yield: 
 Percentage yield is of great importance in industrial perspective, when costly raw 
materials chosen for preparation of nanoparticles. It plays a crucial role in determining 
whether the preparation procedure chosen for incorporating a active compound into the 
polymeric particles was efficient. The overall yield of a procedure is simply expressed as 
 
           % Yield =         The total amount of raw materials added     X     100 
                                                   Amount of nanoparticles 
              The initial amount of raw materials corresponds to the amount of active compound, 
polymer and certain amounts of stabilizing agents or surfactants being adsorbed during the 
preparation. 
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Drug loading: 
 The drug loading or loading content was expressed as 
 
                        Drug loading   =      Amount of the drug in the nanoparticles   
                    Amount of the drug added to the formulation 
% Entrapment efficiency: 
 Drug entrapment efficiency represents the amount of the drug which has been 
incorporated into the polymer matrix or absorbed onto the particle surface.  
 
         %Entrapment Efficiency =           Amount of the drug entrapped     X    100 
                                                               Amount of the drug added 
 Drug loading was done after separation of free drug from bounded drug in 
nanoparticles. drug loading can be determined after ultracentrifugation of a nanoparticulate 
suspension by dissolving the formed sediment with an appropriate solvent to extract the 
entrapped drug from polymer matrices and further subsequent analysis was carried out by 
using methods such as spectrophotometry, spectrofluorophotometry, high performance liquid 
chromatography to determine the amount of drug loaded in the nanoparticles. 
 
Size and Morphology: 
Scanning Electron Microscopy and Photon Correlation Spectroscopy and were used to 
study the particle size and surface characteristics of nanoparticles. 
Scanning Electron Microscopy was widely used in the field of nanotechnology to 
study the surface properties such as type of structure and smoothness of prepared 
nanoparticles. It has high resolution and relatively easy sample preparation.  
Photon Correlation Spectroscopy (PCS) was a laser light scattering method useful to 
the measure the particles ranging from 5nm to 5μm. The average mean sizes of particles were 
determined by this method. 
 
Invitro release studies: 
In vitro release studies should be in principle was useful for the prediction of in vivo 
kinetics. Unfortunately, due to the very small size of the particles, the release rate observed in 
vivo can differ greatly from the release obtained in a buffer solution. 
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Depending on the type of polymer, drug release from nanoparticles can take place 
through following two processes: 
y The drug may diffuse out of the polymer through solid matrix: to allow complete 
release from the polymer. 
y The solvent may penetrate into the interstices of nanoparticles and dissolve the drug, 
which then diffuses into the surrounding medium. 
In vitro release study of entrapped drug in nanoparticles can be studied by several 
experimental methods. Such as 
1. Dialysis bag diffusion 
2. In situ method 
3. Sample and separation techniques 
4. Ultra filtration at low pressure. 
 
Stability of drug nanoparticles [9]: 
 
Stability is one of the important concerns in ensuring efficacy and safety of the 
parentrally administered nanosuspensions. 
The stability problems would arise during preparation, shipping and storage. For 
example because of the high pressure and temperature during preparation can cause 
Crystallinity change in drug particles and during the storage and shipping of the products 
stability problems like crystal growth, agglomeration and sedimentation were seen.  
Therefore, stability problems with drug loaded nanoparticles have drawn a significant 
attention during the nanosuspension preparation. 
The stability issues related to the nanosuspensions were divided into physical and 
chemical stability. 
Physical stability: 
             The common physical stability problems related to nanoparticles were  
• Sedimentation/ creaming 
• Agglomeration and 
• Crystal growth  
 
Sedimentation or creaming issues were generally reduced by decreasing the particles 
size during the suspension preparation. 
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Agglomeration was seen in the thermodynamically unstable suspension because of 
large surface area creates larger surface energy; according to that particles tend to 
agglomeration to minimize the surface energy. The most common strategy to overcome the 
agglomeration was adding stabilisers to the suspensions. The selection of stabilizers was 
based on their ability to provide the wetting properties to the surfaces of particles to prevent 
particles agglomeration. 
 Crystal growths in nanosuspensions were raised due to the changes in the particle size 
and size distribution. A narrow size distribution with uniform particle size and also added 
stabilisers can alleviate effects of crystal growth in colloidal suspensions. 
Chemical stability 
       Chemical stability in nanosuspensions was mainly due to the molecular interactions 
between the interactions between the drugs, polymer and other excipients in the formulation. 
Because of their incompatibility degradation impurities were liberated and were effectively 
analysed by HPLC. These incompatibilities were eliminated by performing preformulation 
studies during the formulation development. 
 
1.5 PHARMACEUTICAL ASPECTS OF NANOPARTICLES: 
Nanoparticles that were prepared from different methods were should be free from 
potential toxic impurities, easier to handle, storage and administration and also they should be 
sterilised if intravenous administration was advocated. 
        The following were three important process parameters that were performed after the 
fabrication of nanoparticles by different processing methods. 
                     They were               a. Purification. 
                                                     b. Freeze drying.  
                                                     c. Sterilisation.    
1.5.1 PURIFICATION OF NANOPARTICLES: 
       Nanoparticles prepared by different methods, might have yield toxic impurities in the 
Nanoparticle formulations which were traces of organic solvents, residual monomers, 
polymerisation catalysts, stabilizers, electrolytes and polymer aggregates. 
       The most commonly used methods to purify the nanoparticulate preparation were  
a. Ultra-centrifugation method. 
b. Dialysis membrane method and 
c. Gel filtration method. 
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Ultra-centrifugation method: 
         In this method the prepared nanoparticle suspension was taken into a centrifuge tube 
and subjected to high centrifugation to sediment the particles at the bottom of tube. By this 
method the residual monomers and excess amounts of stabilizers and electrolytes were 
removed by separating out the supernatant. This method suffers with the problems of more 
time consuming and particle aggregation. 
Dialysis membrane method: 
       By this method low molecular weight impurities and stabilizers were removed by 
dialysing with dialysis fluids. This method cannot separate high molecular weight impurities. 
Gel filtration method: 
      Gel filtration method was an efficient method in removing the low molecular weight 
impurities, residual monomers and polymerisation catalysts but suffers the separation of the 
large polymer aggregates from Nanoparticle suspensions. 
                
                Table.2 Various techniques used for purification of Nanoparticles: 
S. No 
Purification 
methods 
Schematic principle  Remarks 
1  Gel filtration 
High  molecular  weight 
substances  and 
impurities  are difficult  to 
remove. 
2  Dialysis 
  High  molecular  weight 
impurities  are difficult  to 
remove;  time  consuming 
process;  scaling  up  is 
difficult. 
3 
Ultra‐
centrifugation 
Aggregation of particles; 
Time consuming process; 
Scaling up difficult 
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1.5.2 LYOPHILISATION OF NANOPARTICLES [10,11]: 
         
Lyophilisation or freeze drying is a dehydration technique, in which dehydration takes 
place while the product is in a frozen state and under a controlled vaccum condition. 
        Lyophilisation involves the freezing of the Nanoparticle solution and subsequent 
sublimation of its bound and unbound water content under controlled vaccum to get a free 
flowing powder material. 
      
   The following were the advantages of lyophilisation of Nanoparticles 
• Freeze drying of nanoparticles prevents the solubilisation and degradation of 
polymer in the solvents used for formulation. 
• It prevents the drug leakage, desorption and degradation by improving the drug 
association with nanoparticles and also by removing the unbound and bound water 
in the Nanoparticle suspensions. 
• Lyophilised nanoparticles were easy to handle and store and helps in the long term 
preservation of nanoparticles. 
• It preserves the physicochemical properties of prepared nanoparticles like elegant 
freeze dried cake and shorter reconstitution time and unchanged encapsulation 
efficiency. 
• Freeze drying has an accepted method for processing and stabilising heat sensitive 
products like niosomes, nanomicelles and nanoemulsions throughout the storage 
conditions. 
 
Lyoprotectants or Cryopreservatives : 
               Lyoprotectants were used to protect the formulation from stress that was generated 
during freezing and dehydration stages of Lyophilisation. 
Some of the lyoprotectants that were used for lyophilisation were as follows 
• Mannitol 
• Sucrose 
• Poly(vinyl alcohol) 
• Poly(vinyl pyrrolidone)  
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Lyophilisation cycle can be divided into three steps 
 Freezing. 
 Primary drying and 
 Secondary drying 
     1. Freezing step: 
                 Freezing step was a solidification stage in the lyophilisation of the liquid 
suspension; during this stage the water which was in unbound form was freezes into ice 
crystals. This results in the increased concentration of suspension. The concentrated 
suspension gets solidified on further increasing the freezing duration and yields a 
crystalline, amorphous or combined amorphous-crystalline form. The small percentage 
of water that remained in the liquid state and did not freeze was called bound water. 
      2. Primary Drying: 
          During this stage, ice crystals that were formed in freezing step were sublimated 
under controlled vaccum and temperature conditions. At the end of sublimation step 
Porous plugs were formed on the surface of lyophilised cake it represents the spaces 
that were occupied by ice crystals. 
 
3. Secondary Drying: 
    Secondary drying removes the bound water from the product which was not 
sublimated during primary drying.     
 
1.5.3 STERILISATION OF NANOPARTICLES: 
       Nanoparticles which were intended for IV administration should be sterilised thoroughly 
to remove pyrogens which reported to cause the increased levels of endotoxins. 
    The different methods that were used to sterilize the Nanoparticle formulations were  
a. Membrane filters. 
b. Irradiation  technique and 
c. Autoclave methods 
 
Membrane filtration: 
           The nanoparticle suspensions which were having size less than 0.2µm were effectively 
sterilised through the 0.22µm membrane filters than the particles with a size range of 0.25-
1.0µm were did not filtered through the membrane. 
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Irradiation technique:  
In this method the Nanoparticle formulations were subjected to Gamma radiations. 
Heat sensitive formulations were effectively sterilised by this method. 
 
Autoclave method: 
It is a type of aseptic method which completely eliminates the effects of endotoxins 
but was prone to show an impact on the physicochemical properties of nanoparticles like 
particle size, stability and release characteristics. 
 
1.6 AN OVERVIEW OF CANCER CHEMOTHERPHY [12] 
Cancer was a group of neoplastic diseases that occur in human of all age groups and 
races as well as in all animal species. The specific types of cancer are related to multiple 
factors include race, age, sex, genetic predisposition and exposure to the carcinogen. 
Cancer is a disease of uncontrolled cell division and metastatic. It was generally 
considered to be due to the clonal expansion of a singe neoplastic cell.   
Cancer tumors were of two types 
1. Benign tumors, these were non metastatic tumors with limited clonal 
expansion. 
2. Malignant tumors, these were metastatic in nature with uncontrolled cell 
division and harmful effects on physiological processes. 
Mode of action of chemotherapeutic agents [13] 
Most of antineoplastic agents affect cell cycle process during the mitosis by acting 
specifically on processes such as function of mitotic spindle and DNA synthesis. 
Antitumor drugs were better in killing the cancers cells during DNA synthesis and 
active division stage itself because at that stage a tumor was young and also most of its cells 
were making DNA.  
The major problems in cancer chemotheraphy were the toxic drugs effects on normal 
cells and the rapid clearance of the drug from the tumor cells [14]. Rapidly dividing normal 
cell like bone marrow cells involved in the immune defence system were also destroyed by 
the present day chemotheraphy. Hair loss, increased susceptibility to infections and Nausea 
were adverse effects associated with anticancer drugs [15]. 
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1.7 NANOTECHNOLOGY IN ANTICANCER DRUG DELIVERY [16]: 
Nanotechnology based therapeutics in the cancer chemotherapy have the advantages 
of the increased therapeutic drug efficacy, reduced adverse effects or toxicity to normal 
healthy cells and tissues, and improved patient compliance.  
It plays an important role in satisfying the delivery of anticancer drugs particularly to 
the site of action with a minimum effective concentration over a period of time. 
 
Nanosize based drug carriers like polymeric nanomicelles , polymer-drug conjugates, 
solid lipid nanoparticles and polymeric nanoparticles have numerous benefits over the 
conventional dosage forms like injections and oral solids [17]. 
A successful formulation for the delivery of chemotherapeutic agents should have the 
following features 
• It should act as a better therapeutic drug carrier for targeted delivery. 
• They should have longer circulation time. 
• Smaller size to escape from the scavenging effect of phagocytes. 
• They should avoid the opsonisation. 
• They should enhance tumor uptake of drug. 
• And promote endocytosis of drug loaded carrier. 
 
The above features were hold good by delivering the anticancer drugs through the 
polymeric micellar nanotechnology, because they were longer time circulating nanoparticles 
with stealth properties [18]. 
The primary function of micellar drug delivery was to improve the solubility and 
stability of hydrophobic drugs. This was achieved by entrapping the drug in the hydrophobic 
core of polymeric micelle. And the long circulation time, reduced plasma protein binding, 
uptake by phagocytes and RES cells were removed because of the presence of hydrophilic 
shell on the outer surface of nanomicelles [19]. 
The most commonly used nanomicelles in the cancer drug delivery were derived from 
the amphiphilic block copolymers like MPEG-b-PCL copolymer, MPEG-b-PLA copolymer, 
MPEG-b-PLGA copolymer and MPEG-b-PEGMA copolymer. These polymeric micelles 
have capacity to encapsulate the various anticancer drugs such as Paclitaxel , Docetaxel and 
Doxorubicin.  
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So, the polymeric micellar nanotechnology has a very good capability of loading and 
targeting the anticancer drugs in the treatment of various cancer conditions in the human 
body. 
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  2. LITERATURE REVIEW 
 
Kevin Letchford et al., (2009) formulated the Paclitaxel loaded nanomicelles with two 
types of MPEG-b-PCL diblock copolymers, differs in the PCL block lengths of either 19 or 
104 and evaluated the encapsulation efficiency and in vitro release behaviour of these two 
types of Paclitaxel loaded polymeric micelles. The results were showed that the polymeric 
micelles having PCL block length of 104 units have superior encapsulation and release 
behaviour than the PCL block with 19 units. Hence, they concluded that amphiphilic diblock 
copolymers with PCL block length of 104 units were suitable for the preparation of 
Paclitaxel nanomicelles [20]. 
 
T. Musumeci et al., (2006) developed and characterised Paclitaxel loaded poly(lactide) PLA 
and poly (lactide-co-glycolide) PLGA nanospheres by solvent displacement method and 
lyophilised by freeze drying method to increase the stability of nanoparticle formulation for 
longer periods of time to ensure the good physico-chemical properties upon reconstitutions 
and also reported the effects of various lyoprotectants (mono- and disaccharides and poly 
alcohols) at various concentrations on nanoparticles particle size and surface charge 
characteristics [21]. 
 
Hongliang Xin et al., (2010) prepared Paclitaxel nanomicelles by o/w emulsion and 
evaporation technique and evaluated drug loading coefficient (DL%) and encapsulation 
efficiency (ER%) with the different amounts of Paclitaxel, which were co-dissolved with 
polymeric micelle in the processes of polymeric micellar nanoparticles and reported that with 
increase in PTX feeding, the encapsulation efficiency decreased, but the drug-loading 
coefficient increased firstly and then decreased sharply because of the increased hydrophobic 
interactions between PTX molecules and copolymers as the amount of PTX increased [22]. 
 
Xiaowei Dong et al., (2009) developed a Cremophore free lipid based Paclitaxel 
nanoparticles by completely eliminating the mixture of Cremophore EL (polyethoxylated 
castor oil) and dehydrated alcohol which were in the conventional Taxol formulation, 
reported to cause serious side effects such as hypersensitivity reactions after IV in fusion and 
studied in vitro cytotoxicity in human breast cancer MDA-MB-231 cells in comparison with 
Taxol. The lipid based nanoparticles have similar anticancer activity to Taxol [23]. 
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Fang Li et al., (2009) performed an in vitro study of an anti-tumor activity of Paclitaxel-
loaded Chitosan nanoparticles by solvent evaporation and emulsification crosslinking 
method. Cytotoxicity tests showed that the Paclitaxel nanoparticles had higher cell toxicity 
than the individual Paclitaxel and also confocal microscopy analysis confirmed excellent 
cellular uptake efficiency. So, the Chitosan nanoparticles have potential benefits as 
anticancer drug carriers and also have an enhanced anticancer activity [24]. 
 
Soo Young Lee et al., (2008) formulated the Paclitaxel nanoparticles with MPEG-PLGA 
diblock copolymers of different hydrophilic and hydrophobic balances (HLB) by changing 
PLGA segment under constant MPEG segment and described the importance of HLB of 
diblock copolymer in controlling the drug release and storage stability of nanoemulsified 
Paclitaxel [25]. 
 
Rajat Sharma et al., (2011) formulated Paclitaxel loaded PSA-PEG nanoparticles and 
evaluated the influence of different formulation parameters on the particle size, 
encapsulation efficacy and drug release kinetics. The particle size and encapsulation 
efficiency of nanoparticles were gradually increased with polymer concentration and the in 
vitro drug release behaviour was found to be zero order and release in sustained manner for a 
period of 24 hours [26]. 
 
S. Kollipara et al., (2010) developed a liquid chromatographic method for determination of 
Paclitaxel from parentral formulation and nanoparticles. The method was very accurate and 
precise in finding the assay of Paclitaxel in the dosage form. Degradation products formed 
during the stability studies did not effected the detection of Paclitaxel. The peaks were 
remained pure and proved that the method was a stability indicating method [27].  
 
TS Renuga Devi et al., (2010) performed the FTIR and FT Raman spectroscopic analysis of 
Paclitaxel drug and polymeric nanoparticle Paclitaxel drug which has not carried out before. 
They assigned the satisfactory vibration bands by observing the position, shape and relative 
intensities in FTIR and FT-Raman spectra of the drug to study the vibrations of the functional 
derivatives in polymeric nanoparticle Paclitaxel drug. The spectral results indicated that the 
specific functional groups of the polymeric nanoparticle drug material and castor oil-solvent 
based Paclitaxel drug have almost the same chemical characteristics of the pure Paclitaxel 
drug [28]. 
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L. Mu et al., (2003) formulated the Paclitaxel loaded PLGA nanoparticles by using solvent 
evaporation method with different stabilizers such as PVA and Vit E containing TPGS and 
evaluated their effects on particle size and encapsulation efficiency. The results were found 
that the TPGS has reduced the size of nanoparticles and also increased the % EE at lower 
concentrations than compared to the PVA, but with the same stabilizing effects [29].  
 
W.J. Trickler et al., (2008) developed Paclitaxel Nanoparticles Chitosan and Glyceryl 
monooleate by using multiple emulsion solvent evaporation method and evaluated the 
properties like particle size, % EE and in vitro release of prepared nanoparticles. The results 
were indicated that nanoparticles were in size range of 400 to 700 nm with encapsulation 
efficiency of 98 to 100% and in vitro drug release profiles were showed initial burst release 
followed by slow release over the experimental period [30]. 
 
Fabienne Danhier et al., (2009) designed the Paclitaxel loaded PLGA-PEG nanoparticles by 
nanoprecipitation method and evaluated the in vitro antitumoral activity of PTX  by using 
Human cervix cancer cells (HeLa) and compared with the conventional formulations of Taxol 
and Cremophore EL. They observed that the Paclitaxel loaded nanoparticles showed an 
enhanced antitumor activity than the two injection forms. It can be concluded that the 
nanoparticulate delivery of PTX was more efficient in delivering anticancer therapy than 
Taxol and Cremophore EL [31]. 
 
Pei kan et al., (1999) developed the Paclitaxel o/w emulsion with an non ionic surfactant/ 
Egg phosphatidylcholine by sonication and extrusion method. They evaluated the properties 
like globule size, containment efficiency during the stability when stored at 40C for 3 months. 
The results indicated that diameter of globule was found to be around 150 nm with 95% 
efficiency [32]. 
 
Yonglu Wang et al., 2011, developed the Paclitaxel nanosuspension by the homogenisation 
method and evaluated the pharmacokinetic parameters in comparison with Taxol intravenous 
delivery in the rats. In rat plasma, PTX suspension exhibited a decreased AUC, shorter 
elimination life and greater clearance when compared with the Taxol and resulted in greater 
AUC in lung, spleen and liver in contrast with Paclitaxel injection [33]. 
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Eui-Joon Cha et al., (2009) encapsulated Paclitaxel into the polymeric nanomicelles of 
mPEG-Asp-PCL amphiphilic triblock copolymer and stabilized ionically to show the stability 
in aqueous solutions regardless of the concentration and no CMC. They studied the drug 
releasing behaviour in the presence and absence of ionic stabilization and found that 
stabilised nanomicelles showed initial burst release followed by slow and sustained release 
for 2 weeks, in contrast non stabilised micelles showed continued to release drug at a similar 
rate reaching a plateau after a first burst phase release. So, ionically stabilised micelles were 
efficient materials for the development of Paclitaxel polymeric nanocarriers [34]. 
 
Mika Pulkinen et al., (2008) designed Paclitaxel loaded PEG-PEG nanoparticles by 
interfacial solvent displacement method and achieved the high drug encapsulation efficiency. 
The produced nanoparticles were subjected to study the in vitro antitumor activity in glioma 
cell line (BT4C) in comparison with Taxol or the non targeted nanoparticles. The results 
suggested that cytotoxicity of Paclitaxel nanoparticles against BT4C were efficient than 
Taxol [35]. 
 
Michael C. Cochran et al., (2011) formulated the Paclitaxel loaded polymer ultrasound 
contrast agent microbbules for ultra sound triggered drug delivery. The microbubbles were 
subjected to study the effects of loaded PTX on the polymer aucostic properties, drug pay 
load and tumoricidal activity. They observed a maximum pay load of 129.46 µg PTX/mg 
UCA and maintained acoustic properties. In vitro tumoricidal activity of PTX loaded UCA 
triggered with ultrasound waves had shown the sustained and targeted delivery of PTX to 
tumors [36]. 
 
Onkar V Khullar et al., (2011) demonstrated the feasibility of migration and in situ 
Paclitaxel delivery to lymph nodes using an expansile polymer Nanoparticle delivery system 
by NIR imaging, fluorescent microscopy methods. The results revealed that nanoparticles 
with 50 nm only migrated to lymph nodes with appreciable chemotherapy effects of 
Paclitaxel. This confirmed for both Nanoparticle migration and pay load in draining LNs 
have the feasibility of Paclitaxel loaded expansile nanoparticles delivery to lymph nodes [37]. 
 
Chi Yu Huang et al., (2007) formulated Paclitaxel loaded Poly(n-butyl cyanoacrylate) 
nanoparticles having high drug loading and encapsulation efficiency by mini emulsion 
method by using pluronic F127 has a stabiliser and studied the effects of different 
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concentrations of stabilizer on the particle size, EE% and stability of nanoparticles. The 
results indicated that particle size was decreased from 183.4 t0 99.7 nm and EE% was 
increased on increasing stabilizer in the concentration in the range of 0.03 to 0.5% w/v and 
also the stability of particles increased with increased surface coverage with surfactant [38]. 
 
Jin-Oh You et al., (2008) developed the monodispersed pH sensitive Paclitaxel loaded poly 
(N, N- dimethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles by emulsion 
formation and photopolymerisation method for the triggered release of Paclitaxel near tumor 
environment. Tumors have a lower extracellular pH than normal tissues. They showed that 
Paclitaxel release from nanoparticles can be triggered by lower, physiological changes in 
reaching lower pH (0.2-0.6 pH) because the polymer swells and release the drug nearer to 
low pH regions by feedback regulated mechanism [39]. 
 
B.B, Lunderberg et al., (2011) prepared poly (b-amino ester)-PEG-dipalmitoyl 
phosphatidylcholine (PbAE) nanomicelles of Paclitaxel by ultrasonication method using 
synperonic F 108 as a stabilizer and characterised for particle size and stability of 
nanomicelles. The nanomicelles obtained were in the size range of 70 nm with a good 
physical stability at 40C storage condition and also performed the in vitro cell uptake release 
studies of Paclitaxel in comparison with PCL nanoparticles which were previously prepared 
by emulsion solvent evaporation method. The results showed that both uptake and drug 
release were superior with PbAE particles than compared to the PCL particles [40]. 
 
You Ling et al., (2008) prepared the Paclitaxel loaded poly (lactic-co-glycolic) acid by using 
emulsion solvent evaporation technique and used Tocopheryl polyethylene glycol 1000 
succinate as a stabilizer. They evaluated the encapsulation efficiency and in vitro drug release 
by UV spectroscopic method. The results were found that % EE was 67.35% and drug release 
was appeared to be two staged, in the first stage release was burst manner and followed by 
constant release [41].     
 
John K. Jackson et al., (2007) designed Paclitaxel loaded microspheres composed of PLGA 
with amphiphilic block copolymers like PCL and PDLLA by solvent evaporation method and 
evaluated the encapsulation, release rates by using gel permeation chromatography. The 
results were revealed that both copolymers encapsulated at high efficiency in PLGA 
microspheres and the PCL copolymers having PTX were released from microspheres in a 
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short burst over 3 days followed by 10 week very slow release. In contrast with PDLLA 
copolymers were released for 10 weeks from microspheres in a controlled manner. These 
studies indicated that low molecular weight copolymers were effectively encapsulated in 
PLGA microspheres to increase the Paclitaxel release through the micellization process [42]. 
 
Sudhir S. chakravarthi et al., (2010) prepared the Paclitaxel loaded PLGA micro and 
nanoparticles by solvent emulsion solvent evaporation method and compared the cellular 
uptake, drug release and in vitro anti- tumor efficacy of both micro and nanoparticles or the 
commercial TAXOL injection. They found that the PLGA microspheres have increased 
cellular uptake, sustained release and enhanced antitumor efficacy when compared to the 
nanoparticles and TAXOL injection [43]. 
 
Roberta Cavalli et al., (2000) developed and characterised the stealth and non-stealth solid 
lipid nanoparticles of Paclitaxel formed by microemulsion and warm o/w microemulsion 
methods. Both types of SLNs have sizes in nanometer range and also released drug in a slow 
and stable manner throughout the release period without the precipitation of PTX [44]. 
 
Yong Woo Cho et al., (2004) formulated the Paclitaxel loaded poly (ethylene glycol)-block-
poly (phenylalanine) nanomiclles and investigated the influence of hydrotropic agent like 
sodium salicylate on the in vitro drug release of Paclitaxel from polymeric micelle systems. 
In this study they achieved the good sink condition for Paclitaxel by using sodium salicylate 
aqueous solution, which solubilised the PTX more than 10 times the total amount and also 
did not destroy the PEG-b-PPHE micellar structure. So, the hydrotropic agents were useful in 
studying the in vitro release studies of poorly soluble lipophilic drugs from nanomicelles in 
aqueous media [45]. 
 
Yogesh Patil et al., (2009) developed Paclitaxel and Tariquidar loaded biotin ligated PLA-
PEG-PLGA nanoparticles by emsulsion solvent evaporation method and evaluated the tumor 
cell accumulation of nanoparticles and cytotoxicity in drug resistant tumor cells. 
Incorporation of biotin into the nanocarriers increased the cellular uptake of nanoparticles and 
also simultaneous Tariquidar delivery significantly inhibited the growth of resistant tumors at 
a PTX dose that was ineffective without its presence. So, the targeted dual agent 
nanoparticles were a promising way to overcome tumor drug resistence [46]. 
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Jae Sung Lee et al., (2009) formulated and characterised MPEG- PCL Nanoparticles via 
nanoprecipitation method with a systemic change in block ratio of MPEG and PCL, solvent 
choice and organic phase concentrations. The prepared nanoparticles have a dual structure 
with an MPEG shell and a PCL core which were originating from self assembly of MPEG-
PCL copolymer in aqueous solution and the size of nanoparticles was dependent upon two 
sequential processes one is the diffusion between organic and aqueous phases and another 
one is solidification of polymer [47].  
 
Mohammad Reza Nabid et al., (2011) synthesized biodegradable amphiphilic star shaped 
MPEG-PCL copolymer by ring opening polymerisation method and evaluated the properties 
such as hydrodynamic radius, viscosity and micellar stability in comparison with linear 
amphiphilic copolymers. They star shaped copolymers have smaller hydrodynamic radius, 
lower viscosity and improved micellar stability when compared to linear copolymers of 
same molecular weight and composition. They concluded that the developing newer types of 
star shaped copolymers based on PCL and PEG with unique feed ratios may provide novel 
insights in fabricating the superior drug carriers in clinical applications in drug delivery 
systems [48]. 
 
Yodthong Baimark et al., (2009) formulated Ibuprofen loaded MPEG-b-PCL nanospheres 
by emulsification solvent diffusion method and evaluated the influences of PCL block length 
and drug loading content on characteristics of nanospheres and drug release pattern. The 
results where showed that nanospheres with and without drug loading where found of 
spherical shape and smooth surface with a size less than 150nm. Encapsulation efficiency 
was decreased with increase in the PCL length and also drug was released in a sustained 
manner and concluded that drug release rate was depended on the PCL block length and the 
initial drug loading content [49]. 
 
Xintao Shuai et al., (2004) developed the polymeric micellar nanoparticles for Doxorubicin 
delivery with different compositions of diblock copolymers of MPEG-b-PCL and evaluated 
the effects of increasing PCL block length in the copolymer composition on micellar size 
and drug loading content (DL %). The results revealed that increase in the PCL block length 
increases micellar size on increasing PCL length and DL% was significantly less than 
anticipated. They concluded that compromised molecular interactions and PCL crystallinity 
would be the reason for decreased drug loading content [50].   
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Weihui Xie et al., (2007) synthesized the amphiphilic MPEG-PCL diblock copolymers by 
using catalyst yttrium oxide Y (DBMP)3  in the presence of PCL , MPEG has a macro 
initiator by ring opening polymerisation method and controlled the molecular weights of 
copolymers by adjusting MPEG and PCL molar ratios. They characterised the diblock 
structure of the copolymers by 1H NMR spectroscopy and also investigated the thermal and 
crystallisation properties by DSC and POM (polarised optical microscopy). The results were 
indicated that diblock copolymers were linear in structure and crystallization properties were 
depended on length of PCL block lengths as per DSC and POM reports [51]. 
 
Peng Wei Dong et al., (2010) encapsulated the Honokoil, an anticancer drug into the star 
shaped PCL-b-PEG copolymeric nanomicelles by sef assembly without any organic solvent 
by using ultrasonication energy and characterised the obtained nanomicelles for % drug 
loading, EE and in vitro drug release in comparison with free Honokoil. The results were 
found that the % drug loading and EE were higher because of the increased solubility of 
lipophilic drug in hydrophobic core of PCL copolymer. The drug release profiles showed that 
release was in a biphasic manner with initial burst in 8hrs and then slow and controlled 
release for 168 hrs when compared to free Honokoil which was released completely in initial 
burst phase for 8 hrs, it was clearly observed that the release rate of drug from micelles was 
slower than free Honokoil [52]. 
 
Sosnik A et al., (2003) synthesised the MPEG-PCL oligomers by reacting the blends of 
MPEG and PCL in different ratios by ring opening polymerisation method and investigated 
the influence of PCL block length on crystallisable properties of oligomers by DSC analysis,  
because the crystallinity effects the rate of degradation of oligomers. The thermograms of 
DSC showed that oligomers comprising longer PCL blocks (>5) were only crystallized at the 
body temperatures and the oligimers with PCL blocks <5 were able to crystallized at low 
temperatures (4 and 250C) [53]. 
 
Donghui Zheng et al., (2009) developed Docetaxel-loaded MPEG-b-PCL nanoparticles by 
nanoprecipitation method. The obtained nanoparticles were evaluated for encapsulation 
efficiency (%), in vitro drug release and its antitumor efficacy against malignant melanoma 
was evaluated both in vitro and in vivo. The results were indicated that the EE% was high 
because of Docetaxel lipophilicity and also drug was released in a continuous and sustained 
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manner throughout the release study. The in vitro and in vivo studies proved that 
cytotoxicity was achieved in a dose and time dependent manner with good in vitro in vivo 
correlation [54]. 
 
May P Xiong et al., (2008) encapsulated a lipophilic Geldanamycin prodrug in MPEG-b-
PCL micelles by emulsion evaporation method and evaluated the pharmacokinetic 
parameters such as release, AUC, volume of distribution and total clearance in comparison 
with the conventional free Geldanamycin prodrug formulation by in vivo anti tumor activity. 
They results showed that there was a 72 fold enhancement in the AUC, a 21fold decrease in 
volume of distribution, and a 11fold increase in clearance and also drug was released in a 
sustained manner. They suggested that formulating the Geldanamycin prodrug in micellar 
form is a effective way to overcome the problems associated with conventional delivery [55]. 
 
Sa Won Lee et al., (2011) formulated the Docetaxel loaded MPEG-PDLLA nanomicelles 
and evaluated the morphological characteristics such as mean diameter, PDI and 
pharmacokinetic characteristics like in vivo cytotoxicity and hypersensitivity reactions in 
comparison with Docetaxel injection. The prepared micelles were in size range of 10-50nm 
with narrow size distribution. Pharmacokinetic study in mice and Beagle dogs have shown 
the reduced side effects of hypersensitivity reactions and retained the antitumoral activity in 
comparison with Docetaxel injection [56]. 
 
Maria Teresa Peracchia et al., (1997) formulated the PEG-coated amphiphilic diblock and 
multiblock copolymeric nanoparticles by emulsification diffusion method and investigated 
the encapsulation efficacy and in vitro drug release characteristics. The results were indicated 
that %EE and drug release were dependent on chemical composition of hydrophobic core as 
well as the surface density and molecular weight of hydrophilic PEG shell of copolymers [57]. 
 
Lusianna Ostacolo et al., (2010) formulated the Docetaxel loaded PEO-PCL nano micelles 
derived from copolymers of linear triblock and 4-arm star diblock copolymers and evaluated 
the encapsulation efficiency and drug release between two types of copolymers. The results 
were showed that the loading ability and release rate in buffered saline were similar for two 
types of copolymers [58]. 
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Junko Matsumoto et al., (1999) developed Progesterone loaded poly (L-lactide)-poly 
(ethylene glycol)-poly (L-lactide) nanoparticles by solvent evaporation method and evaluated 
drug entrapment and amount of drug release of nanoparticles. The drug entrapment 
efficiencies were around 70% and amount of drug released increased as the PEG content and 
molecular weight of copolymers increased. They concluded that change in the PEG content, 
and PEG Mw could able to control the drug release from the nanoparticles [59]. 
Luis A. Guzman et al., (1996) formulated the nanoparticles using polylactic-polyglycolic 
acid (PLGA) copolymer by emulsification solvent evaporation technique. Fluorescently 
labeled nanoparticles were administered by intraluminal infusion, amount of the nanoparticle 
that reached that reached the target site and biocompatibility were evaluated. Dexamethasone 
was entrapped into the particles to evaluate the therapeutic potential in the prevention of 
neointimal formation. The results were indicated that the nanoparticles successfully 
penetrated into the vessel wall and stayed for up to 14 days after a single intraluminal 
infusion and also significantly decreased neointimal formation [60]. 
Rubianna M. Mainardes et al., (2005) designed the Praziquantel loaded PLGA 
nanoparticles by emulsion solvent evaporation method and studied the effects of formulation 
variables on the particle size distribution of nanoparticles. The results showed that sonication 
time, homogenization speed and time, drug and polymer ratio, PVA % and ratio between 
organic and aqueous phases have the significant effects on the size distribution of 
nanoparticles[61]. 
Chang Gu Keum et al., (2011) formulated the Docetaxel-loaded PLGA nanoparticles by 
Emulsion evaporation technique. They studied the effects of various process parameters such 
as surfactant concentration, sonication time and power, type of evaporation method and 
time, centrifugation speed and initial drug loading that influences the particle size, 
encapsulation and release kinetics of drug loaded nanoparticles and also specified the limits 
for that parameters to achieve better formulation characteristics [62]. 
 
Ganesh. G. N. K et al., (2011) formulated the Docetaxel loaded liposomes by dried thin film 
method and evaluated the in vitro drug release kinetics of the encapsulated drug by fitting the 
dissolution data to the various kinetic models like zero, first order and Korsmeyer- Peppas 
equation. The results were indicated that drug release follows first order kinetics and case II 
transport mechanism of drug release when applied to Korsmeyer-Peppas model [63]. 
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  2. LITERATURE REVIEW 
 
Kevin Letchford et al., (2009) formulated the Paclitaxel loaded nanomicelles with two 
types of MPEG-b-PCL diblock copolymers, differs in the PCL block lengths of either 19 or 
104 and evaluated the encapsulation efficiency and in vitro release behaviour of these two 
types of Paclitaxel loaded polymeric micelles. The results were showed that the polymeric 
micelles having PCL block length of 104 units have superior encapsulation and release 
behaviour than the PCL block with 19 units. Hence, they concluded that amphiphilic diblock 
copolymers with PCL block length of 104 units were suitable for the preparation of 
Paclitaxel nanomicelles [20]. 
 
T. Musumeci et al., (2006) developed and characterised Paclitaxel loaded poly(lactide) PLA 
and poly (lactide-co-glycolide) PLGA nanospheres by solvent displacement method and 
lyophilised by freeze drying method to increase the stability of nanoparticle formulation for 
longer periods of time to ensure the good physico-chemical properties upon reconstitutions 
and also reported the effects of various lyoprotectants (mono- and disaccharides and poly 
alcohols) at various concentrations on nanoparticles particle size and surface charge 
characteristics [21]. 
 
Hongliang Xin et al., (2010) prepared Paclitaxel nanomicelles by o/w emulsion and 
evaporation technique and evaluated drug loading coefficient (DL%) and encapsulation 
efficiency (ER%) with the different amounts of Paclitaxel, which were co-dissolved with 
polymeric micelle in the processes of polymeric micellar nanoparticles and reported that with 
increase in PTX feeding, the encapsulation efficiency decreased, but the drug-loading 
coefficient increased firstly and then decreased sharply because of the increased hydrophobic 
interactions between PTX molecules and copolymers as the amount of PTX increased [22]. 
 
Xiaowei Dong et al., (2009) developed a Cremophore free lipid based Paclitaxel 
nanoparticles by completely eliminating the mixture of Cremophore EL (polyethoxylated 
castor oil) and dehydrated alcohol which were in the conventional Taxol formulation, 
reported to cause serious side effects such as hypersensitivity reactions after IV in fusion and 
studied in vitro cytotoxicity in human breast cancer MDA-MB-231 cells in comparison with 
Taxol. The lipid based nanoparticles have similar anticancer activity to Taxol [23]. 
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Fang Li et al., (2009) performed an in vitro study of an anti-tumor activity of Paclitaxel-
loaded Chitosan nanoparticles by solvent evaporation and emulsification crosslinking 
method. Cytotoxicity tests showed that the Paclitaxel nanoparticles had higher cell toxicity 
than the individual Paclitaxel and also confocal microscopy analysis confirmed excellent 
cellular uptake efficiency. So, the Chitosan nanoparticles have potential benefits as 
anticancer drug carriers and also have an enhanced anticancer activity [24]. 
 
Soo Young Lee et al., (2008) formulated the Paclitaxel nanoparticles with MPEG-PLGA 
diblock copolymers of different hydrophilic and hydrophobic balances (HLB) by changing 
PLGA segment under constant MPEG segment and described the importance of HLB of 
diblock copolymer in controlling the drug release and storage stability of nanoemulsified 
Paclitaxel [25]. 
 
Rajat Sharma et al., (2011) formulated Paclitaxel loaded PSA-PEG nanoparticles and 
evaluated the influence of different formulation parameters on the particle size, 
encapsulation efficacy and drug release kinetics. The particle size and encapsulation 
efficiency of nanoparticles were gradually increased with polymer concentration and the in 
vitro drug release behaviour was found to be zero order and release in sustained manner for a 
period of 24 hours [26]. 
 
S. Kollipara et al., (2010) developed a liquid chromatographic method for determination of 
Paclitaxel from parentral formulation and nanoparticles. The method was very accurate and 
precise in finding the assay of Paclitaxel in the dosage form. Degradation products formed 
during the stability studies did not effected the detection of Paclitaxel. The peaks were 
remained pure and proved that the method was a stability indicating method [27].  
 
TS Renuga Devi et al., (2010) performed the FTIR and FT Raman spectroscopic analysis of 
Paclitaxel drug and polymeric nanoparticle Paclitaxel drug which has not carried out before. 
They assigned the satisfactory vibration bands by observing the position, shape and relative 
intensities in FTIR and FT-Raman spectra of the drug to study the vibrations of the functional 
derivatives in polymeric nanoparticle Paclitaxel drug. The spectral results indicated that the 
specific functional groups of the polymeric nanoparticle drug material and castor oil-solvent 
based Paclitaxel drug have almost the same chemical characteristics of the pure Paclitaxel 
drug [28]. 
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L. Mu et al., (2003) formulated the Paclitaxel loaded PLGA nanoparticles by using solvent 
evaporation method with different stabilizers such as PVA and Vit E containing TPGS and 
evaluated their effects on particle size and encapsulation efficiency. The results were found 
that the TPGS has reduced the size of nanoparticles and also increased the % EE at lower 
concentrations than compared to the PVA, but with the same stabilizing effects [29].  
 
W.J. Trickler et al., (2008) developed Paclitaxel Nanoparticles Chitosan and Glyceryl 
monooleate by using multiple emulsion solvent evaporation method and evaluated the 
properties like particle size, % EE and in vitro release of prepared nanoparticles. The results 
were indicated that nanoparticles were in size range of 400 to 700 nm with encapsulation 
efficiency of 98 to 100% and in vitro drug release profiles were showed initial burst release 
followed by slow release over the experimental period [30]. 
 
Fabienne Danhier et al., (2009) designed the Paclitaxel loaded PLGA-PEG nanoparticles by 
nanoprecipitation method and evaluated the in vitro antitumoral activity of PTX  by using 
Human cervix cancer cells (HeLa) and compared with the conventional formulations of Taxol 
and Cremophore EL. They observed that the Paclitaxel loaded nanoparticles showed an 
enhanced antitumor activity than the two injection forms. It can be concluded that the 
nanoparticulate delivery of PTX was more efficient in delivering anticancer therapy than 
Taxol and Cremophore EL [31]. 
 
Pei kan et al., (1999) developed the Paclitaxel o/w emulsion with an non ionic surfactant/ 
Egg phosphatidylcholine by sonication and extrusion method. They evaluated the properties 
like globule size, containment efficiency during the stability when stored at 40C for 3 months. 
The results indicated that diameter of globule was found to be around 150 nm with 95% 
efficiency [32]. 
 
Yonglu Wang et al., 2011, developed the Paclitaxel nanosuspension by the homogenisation 
method and evaluated the pharmacokinetic parameters in comparison with Taxol intravenous 
delivery in the rats. In rat plasma, PTX suspension exhibited a decreased AUC, shorter 
elimination life and greater clearance when compared with the Taxol and resulted in greater 
AUC in lung, spleen and liver in contrast with Paclitaxel injection [33]. 
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Eui-Joon Cha et al., (2009) encapsulated Paclitaxel into the polymeric nanomicelles of 
mPEG-Asp-PCL amphiphilic triblock copolymer and stabilized ionically to show the stability 
in aqueous solutions regardless of the concentration and no CMC. They studied the drug 
releasing behaviour in the presence and absence of ionic stabilization and found that 
stabilised nanomicelles showed initial burst release followed by slow and sustained release 
for 2 weeks, in contrast non stabilised micelles showed continued to release drug at a similar 
rate reaching a plateau after a first burst phase release. So, ionically stabilised micelles were 
efficient materials for the development of Paclitaxel polymeric nanocarriers [34]. 
 
Mika Pulkinen et al., (2008) designed Paclitaxel loaded PEG-PEG nanoparticles by 
interfacial solvent displacement method and achieved the high drug encapsulation efficiency. 
The produced nanoparticles were subjected to study the in vitro antitumor activity in glioma 
cell line (BT4C) in comparison with Taxol or the non targeted nanoparticles. The results 
suggested that cytotoxicity of Paclitaxel nanoparticles against BT4C were efficient than 
Taxol [35]. 
 
Michael C. Cochran et al., (2011) formulated the Paclitaxel loaded polymer ultrasound 
contrast agent microbbules for ultra sound triggered drug delivery. The microbubbles were 
subjected to study the effects of loaded PTX on the polymer aucostic properties, drug pay 
load and tumoricidal activity. They observed a maximum pay load of 129.46 µg PTX/mg 
UCA and maintained acoustic properties. In vitro tumoricidal activity of PTX loaded UCA 
triggered with ultrasound waves had shown the sustained and targeted delivery of PTX to 
tumors [36]. 
 
Onkar V Khullar et al., (2011) demonstrated the feasibility of migration and in situ 
Paclitaxel delivery to lymph nodes using an expansile polymer Nanoparticle delivery system 
by NIR imaging, fluorescent microscopy methods. The results revealed that nanoparticles 
with 50 nm only migrated to lymph nodes with appreciable chemotherapy effects of 
Paclitaxel. This confirmed for both Nanoparticle migration and pay load in draining LNs 
have the feasibility of Paclitaxel loaded expansile nanoparticles delivery to lymph nodes [37]. 
 
Chi Yu Huang et al., (2007) formulated Paclitaxel loaded Poly(n-butyl cyanoacrylate) 
nanoparticles having high drug loading and encapsulation efficiency by mini emulsion 
method by using pluronic F127 has a stabiliser and studied the effects of different 
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concentrations of stabilizer on the particle size, EE% and stability of nanoparticles. The 
results indicated that particle size was decreased from 183.4 t0 99.7 nm and EE% was 
increased on increasing stabilizer in the concentration in the range of 0.03 to 0.5% w/v and 
also the stability of particles increased with increased surface coverage with surfactant [38]. 
 
Jin-Oh You et al., (2008) developed the monodispersed pH sensitive Paclitaxel loaded poly 
(N, N- dimethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles by emulsion 
formation and photopolymerisation method for the triggered release of Paclitaxel near tumor 
environment. Tumors have a lower extracellular pH than normal tissues. They showed that 
Paclitaxel release from nanoparticles can be triggered by lower, physiological changes in 
reaching lower pH (0.2-0.6 pH) because the polymer swells and release the drug nearer to 
low pH regions by feedback regulated mechanism [39]. 
 
B.B, Lunderberg et al., (2011) prepared poly (b-amino ester)-PEG-dipalmitoyl 
phosphatidylcholine (PbAE) nanomicelles of Paclitaxel by ultrasonication method using 
synperonic F 108 as a stabilizer and characterised for particle size and stability of 
nanomicelles. The nanomicelles obtained were in the size range of 70 nm with a good 
physical stability at 40C storage condition and also performed the in vitro cell uptake release 
studies of Paclitaxel in comparison with PCL nanoparticles which were previously prepared 
by emulsion solvent evaporation method. The results showed that both uptake and drug 
release were superior with PbAE particles than compared to the PCL particles [40]. 
 
You Ling et al., (2008) prepared the Paclitaxel loaded poly (lactic-co-glycolic) acid by using 
emulsion solvent evaporation technique and used Tocopheryl polyethylene glycol 1000 
succinate as a stabilizer. They evaluated the encapsulation efficiency and in vitro drug release 
by UV spectroscopic method. The results were found that % EE was 67.35% and drug release 
was appeared to be two staged, in the first stage release was burst manner and followed by 
constant release [41].     
 
John K. Jackson et al., (2007) designed Paclitaxel loaded microspheres composed of PLGA 
with amphiphilic block copolymers like PCL and PDLLA by solvent evaporation method and 
evaluated the encapsulation, release rates by using gel permeation chromatography. The 
results were revealed that both copolymers encapsulated at high efficiency in PLGA 
microspheres and the PCL copolymers having PTX were released from microspheres in a 
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short burst over 3 days followed by 10 week very slow release. In contrast with PDLLA 
copolymers were released for 10 weeks from microspheres in a controlled manner. These 
studies indicated that low molecular weight copolymers were effectively encapsulated in 
PLGA microspheres to increase the Paclitaxel release through the micellization process [42]. 
 
Sudhir S. chakravarthi et al., (2010) prepared the Paclitaxel loaded PLGA micro and 
nanoparticles by solvent emulsion solvent evaporation method and compared the cellular 
uptake, drug release and in vitro anti- tumor efficacy of both micro and nanoparticles or the 
commercial TAXOL injection. They found that the PLGA microspheres have increased 
cellular uptake, sustained release and enhanced antitumor efficacy when compared to the 
nanoparticles and TAXOL injection [43]. 
 
Roberta Cavalli et al., (2000) developed and characterised the stealth and non-stealth solid 
lipid nanoparticles of Paclitaxel formed by microemulsion and warm o/w microemulsion 
methods. Both types of SLNs have sizes in nanometer range and also released drug in a slow 
and stable manner throughout the release period without the precipitation of PTX [44]. 
 
Yong Woo Cho et al., (2004) formulated the Paclitaxel loaded poly (ethylene glycol)-block-
poly (phenylalanine) nanomiclles and investigated the influence of hydrotropic agent like 
sodium salicylate on the in vitro drug release of Paclitaxel from polymeric micelle systems. 
In this study they achieved the good sink condition for Paclitaxel by using sodium salicylate 
aqueous solution, which solubilised the PTX more than 10 times the total amount and also 
did not destroy the PEG-b-PPHE micellar structure. So, the hydrotropic agents were useful in 
studying the in vitro release studies of poorly soluble lipophilic drugs from nanomicelles in 
aqueous media [45]. 
 
Yogesh Patil et al., (2009) developed Paclitaxel and Tariquidar loaded biotin ligated PLA-
PEG-PLGA nanoparticles by emsulsion solvent evaporation method and evaluated the tumor 
cell accumulation of nanoparticles and cytotoxicity in drug resistant tumor cells. 
Incorporation of biotin into the nanocarriers increased the cellular uptake of nanoparticles and 
also simultaneous Tariquidar delivery significantly inhibited the growth of resistant tumors at 
a PTX dose that was ineffective without its presence. So, the targeted dual agent 
nanoparticles were a promising way to overcome tumor drug resistence [46]. 
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Jae Sung Lee et al., (2009) formulated and characterised MPEG- PCL Nanoparticles via 
nanoprecipitation method with a systemic change in block ratio of MPEG and PCL, solvent 
choice and organic phase concentrations. The prepared nanoparticles have a dual structure 
with an MPEG shell and a PCL core which were originating from self assembly of MPEG-
PCL copolymer in aqueous solution and the size of nanoparticles was dependent upon two 
sequential processes one is the diffusion between organic and aqueous phases and another 
one is solidification of polymer [47].  
 
Mohammad Reza Nabid et al., (2011) synthesized biodegradable amphiphilic star shaped 
MPEG-PCL copolymer by ring opening polymerisation method and evaluated the properties 
such as hydrodynamic radius, viscosity and micellar stability in comparison with linear 
amphiphilic copolymers. They star shaped copolymers have smaller hydrodynamic radius, 
lower viscosity and improved micellar stability when compared to linear copolymers of 
same molecular weight and composition. They concluded that the developing newer types of 
star shaped copolymers based on PCL and PEG with unique feed ratios may provide novel 
insights in fabricating the superior drug carriers in clinical applications in drug delivery 
systems [48]. 
 
Yodthong Baimark et al., (2009) formulated Ibuprofen loaded MPEG-b-PCL nanospheres 
by emulsification solvent diffusion method and evaluated the influences of PCL block length 
and drug loading content on characteristics of nanospheres and drug release pattern. The 
results where showed that nanospheres with and without drug loading where found of 
spherical shape and smooth surface with a size less than 150nm. Encapsulation efficiency 
was decreased with increase in the PCL length and also drug was released in a sustained 
manner and concluded that drug release rate was depended on the PCL block length and the 
initial drug loading content [49]. 
 
Xintao Shuai et al., (2004) developed the polymeric micellar nanoparticles for Doxorubicin 
delivery with different compositions of diblock copolymers of MPEG-b-PCL and evaluated 
the effects of increasing PCL block length in the copolymer composition on micellar size 
and drug loading content (DL %). The results revealed that increase in the PCL block length 
increases micellar size on increasing PCL length and DL% was significantly less than 
anticipated. They concluded that compromised molecular interactions and PCL crystallinity 
would be the reason for decreased drug loading content [50].   
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Weihui Xie et al., (2007) synthesized the amphiphilic MPEG-PCL diblock copolymers by 
using catalyst yttrium oxide Y (DBMP)3  in the presence of PCL , MPEG has a macro 
initiator by ring opening polymerisation method and controlled the molecular weights of 
copolymers by adjusting MPEG and PCL molar ratios. They characterised the diblock 
structure of the copolymers by 1H NMR spectroscopy and also investigated the thermal and 
crystallisation properties by DSC and POM (polarised optical microscopy). The results were 
indicated that diblock copolymers were linear in structure and crystallization properties were 
depended on length of PCL block lengths as per DSC and POM reports [51]. 
 
Peng Wei Dong et al., (2010) encapsulated the Honokoil, an anticancer drug into the star 
shaped PCL-b-PEG copolymeric nanomicelles by sef assembly without any organic solvent 
by using ultrasonication energy and characterised the obtained nanomicelles for % drug 
loading, EE and in vitro drug release in comparison with free Honokoil. The results were 
found that the % drug loading and EE were higher because of the increased solubility of 
lipophilic drug in hydrophobic core of PCL copolymer. The drug release profiles showed that 
release was in a biphasic manner with initial burst in 8hrs and then slow and controlled 
release for 168 hrs when compared to free Honokoil which was released completely in initial 
burst phase for 8 hrs, it was clearly observed that the release rate of drug from micelles was 
slower than free Honokoil [52]. 
 
Sosnik A et al., (2003) synthesised the MPEG-PCL oligomers by reacting the blends of 
MPEG and PCL in different ratios by ring opening polymerisation method and investigated 
the influence of PCL block length on crystallisable properties of oligomers by DSC analysis,  
because the crystallinity effects the rate of degradation of oligomers. The thermograms of 
DSC showed that oligomers comprising longer PCL blocks (>5) were only crystallized at the 
body temperatures and the oligimers with PCL blocks <5 were able to crystallized at low 
temperatures (4 and 250C) [53]. 
 
Donghui Zheng et al., (2009) developed Docetaxel-loaded MPEG-b-PCL nanoparticles by 
nanoprecipitation method. The obtained nanoparticles were evaluated for encapsulation 
efficiency (%), in vitro drug release and its antitumor efficacy against malignant melanoma 
was evaluated both in vitro and in vivo. The results were indicated that the EE% was high 
because of Docetaxel lipophilicity and also drug was released in a continuous and sustained 
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manner throughout the release study. The in vitro and in vivo studies proved that 
cytotoxicity was achieved in a dose and time dependent manner with good in vitro in vivo 
correlation [54]. 
 
May P Xiong et al., (2008) encapsulated a lipophilic Geldanamycin prodrug in MPEG-b-
PCL micelles by emulsion evaporation method and evaluated the pharmacokinetic 
parameters such as release, AUC, volume of distribution and total clearance in comparison 
with the conventional free Geldanamycin prodrug formulation by in vivo anti tumor activity. 
They results showed that there was a 72 fold enhancement in the AUC, a 21fold decrease in 
volume of distribution, and a 11fold increase in clearance and also drug was released in a 
sustained manner. They suggested that formulating the Geldanamycin prodrug in micellar 
form is a effective way to overcome the problems associated with conventional delivery [55]. 
 
Sa Won Lee et al., (2011) formulated the Docetaxel loaded MPEG-PDLLA nanomicelles 
and evaluated the morphological characteristics such as mean diameter, PDI and 
pharmacokinetic characteristics like in vivo cytotoxicity and hypersensitivity reactions in 
comparison with Docetaxel injection. The prepared micelles were in size range of 10-50nm 
with narrow size distribution. Pharmacokinetic study in mice and Beagle dogs have shown 
the reduced side effects of hypersensitivity reactions and retained the antitumoral activity in 
comparison with Docetaxel injection [56]. 
 
Maria Teresa Peracchia et al., (1997) formulated the PEG-coated amphiphilic diblock and 
multiblock copolymeric nanoparticles by emulsification diffusion method and investigated 
the encapsulation efficacy and in vitro drug release characteristics. The results were indicated 
that %EE and drug release were dependent on chemical composition of hydrophobic core as 
well as the surface density and molecular weight of hydrophilic PEG shell of copolymers [57]. 
 
Lusianna Ostacolo et al., (2010) formulated the Docetaxel loaded PEO-PCL nano micelles 
derived from copolymers of linear triblock and 4-arm star diblock copolymers and evaluated 
the encapsulation efficiency and drug release between two types of copolymers. The results 
were showed that the loading ability and release rate in buffered saline were similar for two 
types of copolymers [58]. 
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Junko Matsumoto et al., (1999) developed Progesterone loaded poly (L-lactide)-poly 
(ethylene glycol)-poly (L-lactide) nanoparticles by solvent evaporation method and evaluated 
drug entrapment and amount of drug release of nanoparticles. The drug entrapment 
efficiencies were around 70% and amount of drug released increased as the PEG content and 
molecular weight of copolymers increased. They concluded that change in the PEG content, 
and PEG Mw could able to control the drug release from the nanoparticles [59]. 
Luis A. Guzman et al., (1996) formulated the nanoparticles using polylactic-polyglycolic 
acid (PLGA) copolymer by emulsification solvent evaporation technique. Fluorescently 
labeled nanoparticles were administered by intraluminal infusion, amount of the nanoparticle 
that reached that reached the target site and biocompatibility were evaluated. Dexamethasone 
was entrapped into the particles to evaluate the therapeutic potential in the prevention of 
neointimal formation. The results were indicated that the nanoparticles successfully 
penetrated into the vessel wall and stayed for up to 14 days after a single intraluminal 
infusion and also significantly decreased neointimal formation [60]. 
Rubianna M. Mainardes et al., (2005) designed the Praziquantel loaded PLGA 
nanoparticles by emulsion solvent evaporation method and studied the effects of formulation 
variables on the particle size distribution of nanoparticles. The results showed that sonication 
time, homogenization speed and time, drug and polymer ratio, PVA % and ratio between 
organic and aqueous phases have the significant effects on the size distribution of 
nanoparticles[61]. 
Chang Gu Keum et al., (2011) formulated the Docetaxel-loaded PLGA nanoparticles by 
Emulsion evaporation technique. They studied the effects of various process parameters such 
as surfactant concentration, sonication time and power, type of evaporation method and 
time, centrifugation speed and initial drug loading that influences the particle size, 
encapsulation and release kinetics of drug loaded nanoparticles and also specified the limits 
for that parameters to achieve better formulation characteristics [62]. 
 
Ganesh. G. N. K et al., (2011) formulated the Docetaxel loaded liposomes by dried thin film 
method and evaluated the in vitro drug release kinetics of the encapsulated drug by fitting the 
dissolution data to the various kinetic models like zero, first order and Korsmeyer- Peppas 
equation. The results were indicated that drug release follows first order kinetics and case II 
transport mechanism of drug release when applied to Korsmeyer-Peppas model [63]. 
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                                                 3.1 AIM OF THE WORK 
 
¾ The main objective of the work was to develop a controlled release dosage form of 
Paclitaxel nanoparticles using MPEG-b-PCL amphiphilic block copolymer for 
enhancing solubility of the drug and reducing severe side effects related with the 
solvents in conventional delivery system. 
¾ The Amphiphilic block copolymers have the property of forming the self stabilised 
nanomicelles at their CMC in the aqueous solutions with inner hydrophobic polyester 
core and outer hydrophilic stealth with MPEG. The inner hydrophobic core in the 
nanomicelles has high capability to entrap lipophilic drugs and contributes for 
increased solubility of hydrophobic drug in aqueous solutions.  
¾ Paclitaxel is one of the most commonly used cytotoxic antimicrotubular taxane. It is 
highly lipophilic and insoluble in water, due to the low solubility in water taxanes 
were administered by dissolving in Cremophore EL (polyethoxylated castor oil) and 
ethanol which causes serious side effects like sever hypersensitivity reactions and 
neurotoxicity, when administered intravenously. These severe side effects limit the 
use of conventional dosage form. 
¾  So, the inclusion of this Taxanes in polymeric nanomicelles has proved to be a good 
approach to eliminate side effects of Cremophore EL and improved antitumor 
activity. 
¾ Design of Nanoparticulate drug delivery of Paclitaxel will improve the patient 
compliance, because of the reduced hypersensivity reactions of solvent Cremophore 
EL and non target side effects associated with conventional delivery system. 
¾ The prepared Paclitaxel nanoparticles were further lyophilized by freeze drying 
process to improve the stability of nanoparticles during the storage condition.   
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                                           3.2 PLAN OF THE WORK 
 
IT WAS PLANNED TO CARRY OUT THE PRESENT STUDY AS 
FOLLOWS: 
 
 
STAGE 1:      
Preformulation studies involve the observation of physical and chemical data 
available. The identification of raw materials and preliminary compatibility studies 
between drug and copolymer to be done using infrared spectroscopy. 
 
                                      
STAGE 2:       
Formulation of MPEG-b-PCL nanoparticles with Paclitaxel in various 
Proportions of drug and copolymer by Emulsion solvent evaporation technique. 
                
 STAGE 3: 
 
                     In vitro characterization 
a. Entrapment efficiency 
b. Study on in vitro drug release 
c. Release kinetics 
 
STAGE 4: 
 
                                 Physical characterization of nanoparticles 
 
a. Particle size analysis 
b. Zeta potential 
c. Scanning Electron Microscopy 
                                                           d. Polydispersity index 
 
 
 
 
STAGE 5: 
                                 Short term stability studies 
 
         MATERIALS AND INSTRUMENTS 
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 4. MATERIALS AND INSTRUMENTS 
 
 
 
                                                   
4.1 MATERIALS USED 
 
 
 
 
                          
 
 
 
S.No Ingredients Manufactures 
1. Paclitaxel Celon Laboratories Ltd, Hyderabad. 
2. MPEG-b-PCL copolymer Celon Laboratories Ltd, Hyderabad. 
3. Polyvinyl Alcohol Merck Chemicals, Mumbai. 
4. Dichloromethane Merck chemicals, Mumbai. 
5. Acetonitrile Merck chemicals, Mumbai. 
6. Isopropyl alcohol Merck chemicals, Mumbai. 
7.   PBS  buffer Capsule Sigma Aldrich, USA 
8.   Methanol Merck chemicals, Mumbai. 
9.  Glycerine Fisher scientific, Mumbai. 
. 
10. Potassium Bromide Merck chemicals, Mumbai. 
11.  Water for injection Celon Laboratories Ltd, Hyderabad. 
12. Cellulose acetate membrane 
filters 0.22 µm 
Raylab, New Zealand.
13. Whatman filter papers Madhu chemicals Ltd, Hyderabad. 
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4.2 INSTRUMENTS USED          
 
                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
S.No Instruments  Manufactures 
1. UV spectrophotometer 1601 Shimadzu corporation, Kyoto, Japan.
2.     Infra Red spectroscopy  
 
 Bruker, Germany.
3.   Shear homogenizer   Ika Ultra turrax, Germany. 
4. Rotary vacuum evaporator    Buchi, Germany. 
5.   Lyophilizer    Lyo Lab, LSI, India. 
6.   Electronic Balance  Sartorius, Germany.
7.   Mechanical stirrer  Remi instruments, India. 
8.   Ultra Centrifuge (Beckman)  Centrifuge instruments Ltd, China. 
9.    Bath Sonicator   Intech Labs, Hyderabad, India. 
10. Scanning Electron Microscopy Field instruments, Japan.  
11.   Particle size analyser Malvern, UK.
12. Zeta potential analyser Malvern, UK. 
13. Stability chamber Osworld, Mumbai, India. 
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                                                 5.1 DRUG PROFILE 
Paclitaxel[64] 
Paclitaxel is a drug used in cancer chemotherapy. It is isolated from the bark of the Yew tree, 
Taxous brevifolia. It polymerizes the microtubules and leading to the cell death. 
Paclitaxel is used in the treatment of ovarian and breast cancers [67]. 
Synonyms                                      :     7-epi-Paclitaxel, 7-epi-taxol 
Molecular Formula                      :     C47H51NO14 
Molecular weight                          :     853.9061 g/mol 
 
Molecular Structure [65]: 
                                   
                               
Systematic IUPAC name [66]: 
(1S, 2S, 7R, 10S, 12R)-4, 12-bis(acetyloxy)-1,9-dihydroxy-1-(3S-2-hydroxy-3-phenyl-3-
propoxy-17-methyl-12-oxo-7-heptacyclo[11.3.1] dec-13-en-2-yl benzoate. 
Paclitaxel Identifier: 
CAS Number           :   33069-62-4 
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PHYSICO-CHEMICAL DATA [67, 68] 
Physical description  :    White crystalline solid 
Melting point             :     216-2170C 
Solubility                    :     Freely soluble in ethanol, soluble in dichloromethane,   
                     sparingly soluble in isoproponal and insoluble in water 
Hydrophobicity          :     Log p 3.96   
Dissociation constant :    11.99 
PHARMACOKINETIC DATA [69]  
Absorption                 :     IV infusion 
Bioavailability           :     Oral (< 10%) 
Route               :     Intravenous administration 
Distribution               :     227 to 688 Lt/m2 
Half-life                     :     It shows a distribution half-life of 0.54 hours and  
                              elimination half-life of 5 to 6 hours.   
Protein binding          :    > 90% of the drug is extensively bind to the plasma proteins. 
Metabolism                :     Hepatic metabolism.  
Paclitaxel was metabolized by the cytochrome P450 isozyme.  
Excretion                    :    Less than 10% of the drug is eliminated in unchanged form in   
                               urine and also the smaller amount of drug is eliminated through 
               the faeces. 
Storage Condition     :  2-80C and protected from light.     
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Mechanism of Action[70]: 
Paclitaxel promotes the assembly of microtubules by binding to tubulin dimers and then 
stabilizes microtubules by preventing their depolymerisation. This results in the inhibition of 
dynamic reorganisation of network of microtubules that is essential during the interphase 
stage of mitotic cellular division. 
Pharmacokinetics [71]: 
Absorption: 
Paclitaxel is administered as a 3-hour infusion of 135 to 175 mg/m2 every 3 weeks, or as a 
weekly 1-hour infusion of 80 to 100 mg/m2. Longer infusions (96 hours) have yielded 
significant response rates in breast cancer patients. Pharmacokinetics was assessed by non 
compartment and model independent methods. 
Distribution: 
The average distribution half life of Paclitaxel was 0.34 hours in plasma. About 98% of drug 
is bound to plasma proteins and the presence of antiulcer drugs did not affect protein binding 
of Paclitaxel. 
Metabolism: 
Paclitaxel was metabolized in the liver by Cyt P450 isozyme into 6α-hydroxypaclitaxel. 
Excretion:  
Paclitaxel was mainly excreted by urine. Renal excretion is nonlinear and decreases with 
increased dose. The excretion through fecal route was very less when compared to renal 
excretion. 
Side effects: 
The most common side effects observed with the Paclitaxel are  
• Hair loss. 
• Low red blood cell count (Anaemia). 
• Tired or short of breath. 
• Numbness or tingling in the hands or feet. 
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• Nausea. 
• Abnormal heart beat. 
• Infections. 
• Diarrhoea 
Adverse reactions: 
The most common adverse effects observed with Paclitaxel are 
• Neutropenia. 
• Hypersensitivity reactions. 
• Hypotension. 
• Bradycardia. 
• Peripheral neuropathy. 
• Myalgia/Arthalgia. 
 
Formulations [72, 73]: 
• Ambraxane 100 mg; Nanoparticle albumin-bound paclitaxel. 
• Taxol 5mg/ml; Paclitaxel injection. 
Combinations with other drugs: 
Paclitaxel is sometimes prescribed for lung and breast cancers[74]. AIDS releated kaposis 
sarcoma in combination with the Cisplatin for the treatment of Breast cancer in combination 
with Doxorubicin.  
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5.2 Methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) diblock copolymer[75, 76]:     
 
    Synonym:  
                               MPEG-b-PCL polymer micelle 
    Structure : 
        
                             
                               
Description             :   It is an odourless and tasteless, white (or) off white   
                 semi crystalline powder. 
MPEG content       :    Mn is 5000 g/mol (or) 5 kilo Daltons (or) 114 MPEG units 
 
PCL content           :    Mn is 24,700 g/mol (or) 24.7 kilo Daltons (or) 104 PCL units 
CMC                       :    0.9 Mg/L 
 
Solubility                :     It is freely soluble in Dicholoromethane and insoluble in water 
Melting point         :     Tm of MPEG is 41.90C      
     Tm of PCL is 570C                                                 
viscosity                 :      13 – 20 cp 
Temperature (Tg) :    -450C (glass transition temperature) 
Temperature (Tc) :     580C   (collapse temperature) 
Functional Category:   Entrapping agent, entraps the drug in the polymeric micelle and  
                                        also act as a solubilising agent for hydrophobic drugs [78].        
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Recent developments in drug delivery systems provide promising ways to maximize 
the localization of the drug toward the tumor while minimizing systemic toxicity. Latest 
progress in polymer science has greatly improved the efficiency of drug carriers in 
encapsulating and delivering chemotherapeutics, among which the amphiphilic block 
copolymers have attracted the most interest.  
Amphiphilic block copolymers tend to form polymeric micelles at lower critical 
micellar concentrations with inner hydrophobic core and outer hydrophilic shell[77]. These 
micelles are the promising candidates for hydrophobic anticancer drugs because of the easier 
incorporation into the hydrophobic core without destroying outer shell which is able to 
stabilize the system [78, 79]. 
In most of diblock copolymers the hydrophilic part is MPEG because of its 
hydrophilicity, biocompatibility, low toxicity, negligible antigenicity and immunogenicity[81]. 
It enables nanoparticles to escape from scavenging of the RES after the systemic 
administration[80].    
The hydrophobic blocks, forming the core are composed of biocompatible, 
biodegradable polyesters such as poly(lactic‐co‐glycolic acid) (PLGA), poly(L‐lactic acid) 
(PLLA), poly(caprolactone) (PCL) and have proven to be very effective in solubilising 
hydrophobic drugs. Among them PCL was chosen to be a good hydrophobic core because of 
its good encapsulation ability and slow biodegradability[81, 82]. 
MPEG-b-PCL is an effective amphiphlic diblock copolymer in carrying hydrophobic 
cancer drugs such as Paclitaxel and Docetaxel for controlled and targeted delivery to the 
tumor sites.  
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                                            5.3 Polyvinyl Alcohol[83, 84] 
 
Synonyms:                 Polyviol, vinol, covol, PVA. 
                   
Structure: 
                                                        
                                                 
Molecular form                  :        (C4 H6 O2)n      
Molecular weight              :        30,000 -2, 00,000 
IUPAC name                     :       Ethenol 
Appearance                       :        It is an odourless, Flake White and granular or semi 
                                         crystalline powder. 
Solubility                           :        Soluble in water and insoluble in Methanol, Acetone 
Functional category          :        Emulsifying agent or Stabilizing agent. 
Melting point                    :        2300C  
 Boiling point                    :        2280C  
 Viscosity                           :        20-28 Mpa.s 
 pH value                          :        5-7 for a 1% w/w aqueous solution. 
Functional category         :         Non-ionic surfactant and Viscosity builder. 
Applications                    :       Used in the topical formulations, particularly in ophthalmic
          products as a viscosity builder and stabilizer in emulsions.      
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Storage              :      PVA undergoes slow degradation at 1900C and rapid degradation 
             at 2000C. So, it was stored at room temperature.  
 
Importance of Stabilizer [41, 85]:   
Stabilizer was used to stabilize the dispersed phase droplets formed during            
emulsification and inhibit coalescence. Surfactants or emulsifiers were act as stabilizers. 
Surfactants were amphipathic in nature and hence align themselves at the droplet 
surface to promote stability by lowering the free energy at the interface between two phases, 
moreover the creation of a charge or steric barrier at the droplet surface confers resistance to 
coalescence and flocculation. 
The amount and the type of emulsifier used play a significant role in determine the 
morphology, size, encapsulation efficiency and release profile. 
The higher amounts of stabilizers in Nanoparticle formulations causes the changes 
such as  
• Bio-degradability. 
• Bio-distribution. 
• Particle cellular uptake. 
• Drug release behaviour. 
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                              6. EXPERIMENTAL INVESTIGATIONS 
 
6.1 STANDARD CALIBRATION CURVE OF PACLITAXEL[41]: 
By UV spectroscopic method: 
Paclitaxel was estimated spectroscopically at 227 nm and it obeys Beer-Lamberts 
law in the range of 5-40 µg/ml. 
 Solvent media:  
                 The solvent media used was a mixture of 50:50 v/v of Acetonitrile: pH 7.4 
Phosphate buffer saline. 
a) Preparation of pH 7.4 Phosphate buffer Saline solution: 
              One PBS capsule (Sigma Aldrich) was dissolved in 200 ml of deionized water and 
yields a pH of 7.4 at 250C. 
b) Preparation of stock solution: 
         Accurately weighed 100 mg of Paclitaxel was taken into the 100 ml standard flask and 
dissolved with 100ml of solvent to get a solution concentration of 1000 µg/ml. 
c) Preparation of sample solution: 
              From the stock solution aliquots ranging from 0.5 to 4 ml were pipetted out and 
diluted 100ml with PBS pH 7.4 to get the concentrations of 5, 10, 15, 20, 25, 30, 35 and 
40µg/ml respectively. Then, the absorbance of each solution was measured at 227 nm UV 
spectrphotometrically against drug free solvent media as blank. Absorbance values were 
plotted against respective concentrations to establish a standard calibration curve. 
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STANDARD CALIBRATION CURVE OF PACLITAXEL: 
 
                                                        
                                                            
                        Table No: 5 Standard readings of Paclitaxel by UV spectroscopy 
 
 
 
S. No. Concentration 
 
(µg/ml) 
Absorbance at 227nm 
1. 5 0.121 
2 10 0.239 
3. 15                  0.351 
4. 20                  0.463 
5. 25                  0.579 
6. 30 0.696 
7. 35  0.806 
8. 40 0.911 
 
Graph No: 1 Standard graph of Paclitaxel in 50:50 v/v Acetonitrile : pH 7.4 PBS 
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The linear equation was obtained as 
                                      R2 = 0.999 and  Y = 0.022x+0.006 
Correlation coefficient value (R2) indicated that there was a linear correlation between 
concentration and absorbance. 
From the standard calibration curve of drug it was concluded that, the paclitaxel obeys Beer-
Lambert’s law in the concentration range of 5-40 µg/ml. The absorbance values and standard 
curve were shown in Table No: 5 and Graph No: 1. 
6.2 PREFORMULATION STUDIES: 
Compatibility studies by IR Spectroscopy [86, 87, 28]: 
Infrared spectroscopic analysis measures the selective absorption of light by the vibration 
modes of specific chemical bonds in the sample.         
IR spectroscopy was used to identify and predict any interactions or incompatibilities 
between the components in the formulation. Therefore, in the present work, a study was 
carried out using IR spectrophotometer to confirm the absence of any possible chemical 
interactions between the drug, polymer and other excipients in the formulation. 
In the present study, the following IR spectra were recorded 
a) Pure sample of Paclitaxel. 
b) MPEG-b-PCL copolymer. 
c) Polyvinyl alcohol. 
d) A mixture of Paclitaxel and MPEG-b-PCL copolymer. 
e) A mixture of Paclitaxel and MPEG-b-PCL copolymer and PVA. 
One part of sample and three parts of potassium bromide of IR grade were triturated 
in mortar. A small amount of triturated sample was taken into a pellet maker and compressed 
at 15 tons pressure in hydraulic press to form a semi transparent pellet. Then the pellet was 
kept in sample holder and was scanned from 4000 to 400 cm-1 in IR spectrometer (Bruker) 
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and the peaks were identified. IR spectra was compared and checked for any shifting in 
functional peaks and non involvement of functional groups. 
The compatibility between the drug, copolymer and other excipients were evaluated by using 
IR peak matching method. 
The spectra and their interpretations with pure drug are as follows   
                                 
 
                                   Table: 06 IR spectra of pure Paclitaxel: 
     
 
 
 
                         
                          
 
 
 
 
 
                           
                       
                         
Frequency ( cm-1) Groups assigned 
3440.65           O- H stretching 
2944.36 C-H Aromatic stretching 
1646.87           C = O stretching 
1370.32           C - N stretching 
1096.62           C-O stretching 
984.12           C- H in plane bending 
632.40 C- H out plane bending 
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                         Table: 07 IR spectra of MPEG-b-PCL copolymer: 
Frequency ( cm-1)         Groups assigned 
3449.38       O - H stretching  
2959.20 C-H Aromatic stretching 
1640.23       C = O stretching 
1374.79       C - N stretching 
1103.13       C-O stretching 
982.91       C- H in plane bending 
644.98 C- H out plane bending 
 
                            Table: 08 IR spectra of Poly vinyl alcohol: 
Frequency ( cm-1)          Groups assigned 
3406.10           O- H stretching  
1649.61           C = O stretching 
1378.69           C - N stretching 
1096.28           C-O stretching 
946.08           C- H in plane bending 
652.27       C- H out plane bending 
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             Table: 09 IR spectra of Paclitaxel and MPEG-b-PCL copolymer: 
Frequency ( cm-1)           Groups assigned 
3440.28          O- H stretching 
2944.49         C-H Aromatic stretching 
1646.70           C = O stretching 
1370.50           C - N stretching 
1095.64           C-O stretching 
983.17           C- H in plane bending 
632.53         C- H out plane bending 
 
  Table: 10 IR spectra of Paclitaxel and MPEG-b-PCL copolymer   
                    and Poly vinyl alcohol: 
Frequency ( cm-1) Groups assigned 
3440.53       O- H stretching 
2944.36      C-H Aromatic stretching 
1646.87        C = O stretching 
1370.75        C - N stretching 
1095.92        C-O stretching 
983.99        C- H in plane bending 
632.93      C- H out plane bending 
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                                 SPECTRA NO: 1 FTIR OF PACLITAXEL 
 
                                                      EXPERIMENTAL INVESTIGATIONS 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai   Page 47 
 
 
                          SPECTRA NO: 2 FTIR OF MPEG-b-PCL COPOLYMER 
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                                SPECTRA NO: 3 FTIR OF POLYVINYL ALCOHOL 
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                         SPECTRA NO 4: FTIR OF MPEG-b-PCL & PACLITAXEL            
                    
                                                      EXPERIMENTAL INVESTIGATIONS 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai   Page 50 
 
    
           
          SPECTRA NO: 5 FTIR OF PACLITAXEL, MPEG-b-PCL AND PVA 
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                  Table No: 11 Interpretations of FTIR Spectra for pure Paclitaxel drug. 
Functional Groups Assessment peaks of pure 
drug( cm-1) 
Range of 
Groups ( cm-1) 
  O- H stretching 3440.65       3450-3250 
  C-H Aromatic stretching 2944.36 2973-2547 
  C = O stretching 1646.87       1850-1550 
  C - N stretching 1370.32       1390-1300 
  C-O stretching 1096.62       1260-1000 
  C- H in plane bending 984.12       941-803 
  C- H out plane bending 632.40        < 700 
 
       Table No: 12 Interpretations of FTIR Spectra for pure drug and drug copolymer
                                                            mixture    
Functional Groups Assessment peaks of 
pure drug ( cm-1) 
Assessment peaks of drug, 
copolymer ( cm-1) 
  O- H stretching 3440.65 3440.28 
  C-H Aromatic stretching 2944.36 2945.49 
  C = O stretching 1646.87 1646.70 
  C - N stretching 1370.32 1370.50 
  C-O stretching 1096.62 1095.64 
  C- H in plane bending 984.12 983.17 
  C- H out plane bending 632.40 632.53 
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    Table No: 13 Interpretations of FTIR Spectra for pure drug and drug, copolymer & 
     PVA mixture 
 
Functional Groups Assessment peaks of 
pure drug ( cm-1) 
Assessment peaks of Drug, 
copolymer & PVA ( cm-1) 
  O- H stretching 3440.65 3440.53 
  C-H Aromatic stretching 2944.36 2944.36 
  C = O stretching 1646.87 1646.87 
  C - N stretching 1370.32 1370.75 
  C-O stretching 1096.62 1096.92 
  C- H in plane bending 984.12 983.99 
  C- H out plane bending 632.40 632.93 
 
 
            
              It was observed that the assessment peaks which were seen in the IR spectra of 
pure Paclitaxel were also appeared in the Paclitaxel, copolymer and PVA mixture, which 
confirmed the absence of any chemical interactions between the drug, copolymer and 
other excipients. The results were shown in Table No: 11, 12 and 13 and Spectra No: 1, 2, 
3, 4 and 5. 
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6.3 PREPARATION OF PACLITAXEL NANOPARTICLES[41] 
6.3.1 Procedure for the preparation of Paclitaxel nanoparticles 
               The preparation of nanoparticles with MPEG-b-PCL copolymer was carried out by 
Emulsion solvent evaporation technique. 
              All the batches of nanoparticles were prepared by emulsion solvent evaporation 
technique. For the preparation of nanoparticles, organic and aqueous solutions were required. 
Preparation of organic solution:  
       Composition:     Dichloromethane - 2 ml 
                                   Paclitaxel - 40 mg 
                                   MPEG-b-PCL copolymer- Quantities were specified in table no: 3  
Accurately weighed 40 mg of the Paclitaxel was dissolved into1.5 ml of dichloromethane 
solvent, then added an accurately weighed quantity of MPEG-b-PCL copolymer as specified 
in the table no: (14) to the previously dissolved 1.5 ml organic solution then add remaining 
0.5 ml DCM solvent and sonicated for 10mins in the bath sonicator for the complete 
solubility of drug and copolymer.   
Preparation of Aqueous solution: 
       Composition:     Poly vinyl alcohol: 200 mg 
                                  Water for Injection: quantity sufficient 
Accurately weighed 200 mg of PVA was dissolved into the 100 ml of WFI at 650C with 
frequent stirring for preparing 0.2% PVA solution and then filtered through the 0.2 micron 
whatmann membrane filter under vaccum. From this, 20 ml of solution was taken for 
emulsion preparation. The PVA solution was used as a stabilizer to stabilize the formed 
emulsion droplets. 
For the stable emulsion preparation, the organic and aqueous solutions were should be in the 
ratio of 1:10. 
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EMULSION SOLVENT EVAPORATION METHOD: 
                 In this method organic solvent was evaporated during the process of Nanoparticle 
formulation.  
           The organic solution containing the drug and polymer was added drop wise into 
aqueous solution of PVA (0.2%) for 1minute through the micropipette during the 
homogenization under high shear homogenizer at 12,000 rpm. The homogenization was 
carried out for 10-15 min under ice bath for the better entrapment of drug into the copolymer 
matrix. 
            After that, the homogenized solution was stirred at 8000 rpm with mechanical stirrer 
for 1hour at room temperature. During this step the formed nanoparticles were hardened and 
organic solution is slowly evaporated. For removing the traces of Dichloromethane in the 
aqueous solution, the solution was evaporated by using Rotary evaporator (Buchi) at 250C 
with 40 rpm for 30 min by applying a vaccum of about 25 mm Hg. 
           Filter the Nanoparticle solution through cellulose acetate membrane filter, under 
vaccum to get the sterile formulation. Then, the collected nanoparticles were redispersed in 
20 ml of Water for injection for lyophilisation. Here, the PVA over the particles was 
dissolved in to the solution and act as a lyoprotectant for protecting the formulation against 
the freezing and drying stress during freeze drying [10]. 
Finally, the Nanoparticle suspension was transferred into a 50 ml glass vial and sealed with a 
rubber stopper followed by an over seal (aluminium) and then wrapped in aluminium foil to 
protect from light. Then, the glass vials were stored in refrigerated condition.  
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               TABLE: 14 COMPOSITIONS OF PACLITAXEL NANOPARTICLES   
  S.No Formulation code      Amount of   
drug(mg) 
Amount  of 
copolymer (mg) 
Drug: carrier  
ratio 
   1.           F1      40          140       1:3.5 
   2.           F2       40           160       1: 4 
   3.           F3       40           180       1:4.5 
  4.           F4       40           200        1: 5 
  5.           F5       40           220        1:5.5 
  6.           F6       40           240        1: 6 
  7.           F7       40           260        1:6.5 
  8.           F8       40           280        1: 7 
  9.           F9       40           300        1:7.5 
  10.           F10       40           320         1: 8 
         
                
             From the above formulations, the best formulation was selected based on the amount 
of the drug loaded or percentage entrapment efficiency and in vitro drug release behaviour. 
Then, the selected or optimised formulation was further lyophilised by freeze drying method 
to increase the stability of nanoparticle formulation during storage. 
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6.3.2 Freeze drying method to lyophilise the Nanoparticle formulation: 
            Lyophilisation or freeze drying has become an accepted method of processing heat 
sensitive products that require long term storage at temperatures above freezing. During the 
freeze drying dehydration of aqueous solution (unbound and bound water) was carried, while 
the product suspension was in a frozen state, under a controlled vaccum condition. 
As per the Entrapment efficiency (%) and in vitro drug release results, formulation F7 was 
found to be desirable than other formulations. Hence, it was chosen for freeze drying or 
lyophilisation.  
Lyophilisation of Nanoparticle formulation was carried out in three stages[11] 
a) Freezing (solidification). 
b) Primary drying. (ice sublimation) 
c) Secondary drying. ( desorption of unfrozen water) 
Freezing:  
During this step the Nanoparticle suspension was freezed at -450C for 490 min, then the 
liquid suspension is cooled and ice crystals are formed and the suspension becomes 
concentrated. Total duration of freezing was 565 minutes. At the end of freezing step, the 
concentrated suspension was in an amorphous form or combined amorphous-crystalline form. 
Primary Drying: 
In the primary drying, the ice crystals that were formed in the frozen product were sublimated 
at 250C under controlled vaccum of 60-65 MT for 2200 min. The total duration of PD was 83 
hour. At the end of drying, porous plugs were formed those represents the spaces occupied by 
ice crystals. 
Secondary drying: 
In the secondary drying, bound water present in the product was removed at 350C under 
controlled vaccum of 65 MT for 630 minutes, which was not separated out as ice during the 
freezing was removed. 
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The three stages were detailed in the following freeze dried nanoparticle recipie [92]. 
 
 
 
6.3.3 Reconstitution of lyophilised Nanoparticle formulation: 
Finally, the formed lyophilised cake was reconstituted slowly with 20 ml of pH 7.4 phosphate 
buffer saline for 1min to prevent foaming and allowed to settle for 5 minutes for proper 
wetting of the lyophilized cake and then gently swirl or invert the vial slowly for at least 2 
minutes until complete dissolution of any cake/powder occurs. 
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6.4 EVALUATION OF PACLITAXEL NANOPARTICLES: 
6.4.1 PHYSICAL CHARACTERISATION OF NANOPARTICLES: 
The optimised Nanoparticle formulation before and after the freeze drying were evaluated by 
studying their physical properties like 
• Particle size analysis 
 
• Polydispersity index 
 
• Zeta potential analysis 
 
• SEM analysis 
 
6.4.1.1 Particle size Analysis: 
            The paclitaxel loaded nanoparticles before and after lyophilisation technique were 
subjected to Laser diffraction particle size analysis for determining the Nanoparticles size and 
their distribution. It was carried out by MALAVERN INSTRUMENTS in Indian institute of 
chemical technology. Hyderabad. 
6.4.1.2 Zeta potential analysis: 
            Zeta potential is an important physical characteristic that evaluates the potential 
stability of colloidal systems. It is an aid in predicting long-term stability of colloidal 
dispersions. 
The significance of zeta potential was that if the particles in the suspension have a large 
negative or positive zeta potential then they will tend to repel each other and they were 
electrically stabilized. However, if the particles have low zeta potential values then there will 
be no force to prevent particles coagulation or flocculation. 
The prepared nanoparticles were subjected to zeta potential analysis before and after 
lyophilisation by MALVERN ZETASIZER V 6.01 in Indian institute of chemical 
technology. Hyderabad. 
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6.4.1.3 Polydispersity index [88]: 
 Polydispersity index is an index or variation or spread with in the particle size distribution of 
a given dispersion sample. It was carried out along with particle size analysis by Malvern 
instruments in IICT, Hyderabad. 
   
6.4.1.4 Scanning electron microscopy: 
Determination of surface morphology (spherical structure, smoothness and formation of 
aggregates) of nanoparticles before and after the lyophilisation were carried out by scanning 
electron microscopy. Samples for SEM were mounted on metal studs and were magnified to 
X 5000.  
6.4.2 INVITRO CHARACTERIZATION OF NANOPARTICLES: 
6.4.2.1 Entrapment Efficiency: 
The Entrapment efficiency of Nanoparticle preparation was determined by UV absorbance of 
drug at 227 nm by UV spectrophotometry [41].  
Nanoparticle suspension was subjected to the ultracentrifugation at 14,000 rpm for 30 mins to 
remove the supernatant containing excess of Paclitaxel, the sediment was formed at the 
bottom of the centrifuge tube. It was vortexed with 2 ml Dichloromethane for 15 min to 
extract the entrapped drug from the core of the nanoparticles. And add the solvent media 
(Acetonitrile : pH 7.4 PBS 50: 50 v/v) to the  solution to solubilise the released drug then 
purged with nitrogen gas to evaporate the dichloromethane[85], until the clear solution is 
obtained. After that, the solution is filtered through the 0.2 micron syringe filter to remove the 
polymer aggregates. 
The 1ml of filtered solution was taken and suitably diluted with solvent media. Then, the   
absorbance of diluted solution was measured spectrophotometrically and the drug 
concentration in the filtered solution was obtained by comparison with the standard 
calibration curve which previously constructed. 
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The following equation was used to find out entrapment efficiency of paclitaxel in 
Nanoparticle formulation  
 
Entrapment efficiency(%)  =    Amount of Drug entrapped       X   100   
                      Amount of drug used for preparation 
 
For all batches, EE (%) was performed in triplicate and the average result was calculated. 
The entrapment efficiency was also performed for the optimised lyophilised formulation F7. 
 
The best formulation is the one which has good entrapment efficiency and desired drug 
release profile. So, it was decided to do the in vitro drug release studies for all the 
formulations. 
 
6.4.2.2 In-vitro drug release studies: 
By UV spectrophotometric method[41]: 
In vitro release of Paclitaxel from Nanoparticle formulation was carried out by using dialysis 
bag diffusion technique[22]. 
The prepared Nanoparticle formulation was placed in a dialysis bag membrane having 
molecular weight cut off 14,000 daltons, which was previously soaked for overnight, both the 
ends were tied tightly and dropped into a beaker containing 200 ml of diffusion solvent 
medium pH 7.4 PBS, maintained at 370C and stirred with the help of a magnetic stirrer. 
Aliquots (1ml) of release medium were withdrawn at different time intervals (8, 16, 24, 32, 
40, 48, 56, 64, 72, 80, 88 and 96 hr) and the sample was replaced with same amount of fresh 
solvent medium to maintain the constant volume. 
Then, the samples were diluted with (Acetonitrile : pH 7.4 PBS 50: 50 v/v) and analysed 
spectrophotometrically at 227 nm. The percentages of drug released at different time intervals 
were calculated from standard calibration curve and the results were tabulated. 
The release study was also performed for the lyophilised formulation F7 after reconstitution 
with 20 ml pH 7.4 PBS. 
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6.4.2.3 Release kinetics[89,88] 
           To analyze the in vitro release data of Nano formulations, various kinetic models were 
used to describe the release kinetics. The zero order release states that drug release rate 
was independent of its concentration.  The first order release describes, the release rate 
from the system was concentration dependent. Higuchi described the release of drugs from 
insoluble matrix as a square root of time dependent process was based on Fickian diffusion. 
The results of in vitro release profile obtained for an optimised freeze dried F7 formulation 
were plotted in modes of data treatment as follows: 
1.   Zero - order kinetic model – Cumulative % drug released versus time. 
2.   First -order kinetic model – Log cumulative percent drug remaining versus time. 
3.   Higuchi’s model – Cumulative percent drug released versus square root of time. 
4.   Korsmeyer equation / Peppa’s model – Log cumulative percent drug released versus 
log time. 
 
a. Zero order kinetics: 
 
Zero order release would be predicted by the following equation: 
At = A0 – K0t 
 
Where 
 
At = Drug release at time‘t’ 
 
A0 = Initial drug concentration. 
 
K0 = Zero- order rate constant (hr-1) 
 
When the data is plotted as cumulative percent drug release versus time, if the plot is linear 
then the data obeys Zero – order kinetics and its slope is equal to Zero order release constant 
K0. 
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b. First order kinetics: 
 
First - order release could be predicted by the following equation: 
 
 
 
Log C = log C0 – Kt / 2.303 
 
Where, 
 
C = Amount of drug remained at time‘t’ 
 
C0  = Initial amount of drug. 
 
K = First - order rate constant (hr-1). 
 
When the data plotted as log cumulative percent drug remaining versus time, yields  a  
straight  line,  indicating  that  the  release  follows  first  order  kinetics. The constant ‘Kt’ 
can be obtained by multiplying 2.303 with the slope value. 
 
c. Higuchi’s model: 
 
 
Drug release from the matrix devices by diffusion has been described below 
 
Higuchi’s classical diffusion equation:  
                              Q = [DЄ / τ(2A – ЄCs ) Cs t]1/2 
Where, 
 
Q = Amount of drug release at time ‘t’ 
 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = Solubility of drug in the matrix. 
Є = Porosity of the matrix. 
τ = Tortuosity. 
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t = Time (hrs at which q amount of drug is released. 
Above equation can be simplified assumed that ‘D’, ‘Cs’ and ‘A’ are constants. Then the 
equation becomes 
                                                              Q = Kt1/2 
 
According to the equation, if cumulative drug release versus square root of time yields a 
straight line, indicating that the drug was released by diffusion mechanism. 
 
d. Korsmeyer equation / Peppa’s model[91]: 
 
 
 
Korsmeyer described a simple relationship to find the mechanism of drug release from 
polymeric system. To study the mechanism of drug release from the Nanoparticle 
formulation, the release data was fitted to the Korsmeyer-Peppa’s law equation, which was 
used to describe the drug release behaviour from polymeric systems. 
 
Mt / Mα = Ktn 
 
Where, 
 
Mt / Mα = Fraction of drug released at time‘t’. 
 
K = Constant 
n = Diffusion exponent related to the mechanism of the release. 
 
 
Above equation can be simplified as follows by applying log on both sides, 
Log Mt / Mα = Log K+ n Log t 
 
In the above equation, “n” value was used to characterize the various release mechanisms as 
mentioned in the table below 
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           Table 15: Diffusion exponent and solute release mechanism for cylindrical shape 
 
S.No Diffusion Exponent (n) Overall solute 
diffusion mechanism 
1. 
 
 
0.45 
 
      Fickian diffusion 
 
2. 
 
 
    0.45<n<0.89 
 
Anomalous (non-Fickian) 
Diffusion 
3.   
    0.89 
 
        Case-II transport 
4.   
    n>0.89 
 
   Super case-II transport 
 
 
 
 
                                                        
6.5 STABILITY STUDIES OF PACLITAXEL NANOPARTICLES [92]: 
The formulation F7 was chosen for stability studies because the entrapment efficiency 
and percentage drug release was high when compared to other formulations and also it 
was lyophilised. The lyophilized Nanoparticle formulations of F7 were kept for three 
months at 50C and 250C/65% RH in a stability chamber (Osworld). At the time interval 
of one month samples were withdrawn from the stability chamber and evaluated the 
following characteristics for 3 months. 
A) Entrapment efficiency (%) 
B) In vitro drug release                            
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7. RESULTS AND DISCUSSION 
 
7.1 In vitro characterisation 
 
7.1.1 Entrapment efficiency of Paclitaxel nanoparticles 
 
The entrapment efficiency (%) of the Paclitaxel loaded Nanoparticle formulations (F1, F2, 
F3, F4, F5, F6, F7, F8, F9 and F10) and an optimised freeze dried formulation F7 was 
determined and tabulated.  
     
        Table No:16 Entrapment efficiency of formulations with drug and copolymer                                   
             Before lyophilisation (n=3), values were the mean of 3 experiments ± S.D 
S.N0 
Formulation 
code 
Amount of drug 
entrapped(mg) 
Percentage 
Entrapment efficiency 
1. F1 16.31±0.17 40.76±0.28 
2. F2 17.12±0.13 42.81±0.32 
3. F3 20.13±0.42 50.34±0.80 
4. F4 27.73±0.45 68.72±0.73 
5. F5 30.07±0.24 75.19±0.60 
6. F6 33.30±0.19 83.26±0.56 
7. F7 36.79±0.17 92.0±0.36 
8. F8 35.07±0.32 87.6±1.08 
9. F9 33.02±0.36 82.57±0.78 
10 F10 31.09±0.33 77.78±1.08 
 
     Table No: 17 Entrapment efficiency of formulation F7 with drug and copolymer                                
                            After lyophilisation (n=3). Values were Mean ± S.D 
 
S.N0 
Formulation 
code 
Amount of drug 
entrapped(mg) 
Percentage 
Entrapment efficiency 
1. F7 36.76±0.14 91.96±0.18 
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 Graph No: 2 Amount drug loaded plot for F1, F2, F3, F4, F5, F5, F6, F7, F8, F9, F10
 Formulations. All the values were plotted by using Mean± S.D (n=3). 
 
               
 
Graph No: 3 Percent Entrapment efficiency plot for F1, F2, F3, F4, F5, F5, F6, F7, F8, 
 F9, F10 Formulations, All the values were plotted by using Mean± S.D (n=3). 
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The % entrapment efficiency was determined by ultracentrifugation method and it 
was found that the formulations F1, F2 and F3 has showed entrapment efficiencies of 
40.76±0.28%, 42.81±0.32%, 50.34±0.80% with drug loading contents of 16.31±0.17mg, 
17.12±0.13mg and 20.13±0.42mg respectively. The low % entrapment efficiencies were due 
to lower drug loading contents because of lesser availability of PCL carboxyl groups of 
copolymer to entrap the drug.  
The formulations F4, F5 and F6 has showed the entrapment efficiencies of 
68.72±0.73%, 75.19±0.60%, 83.26±0.56% with drug loading contents of 27.73±0.45mg, 
30.07±0.24mg and 33.30±0.19mg respectively. The % entrapment efficiencies were 
increased with increase in loading contents because of increased copolymer concentrations 
with respect to the drug and also due to availability of PCL carboxyl groups of copolymer to 
entrap the drug. 
The F7 formulation has showed entrapment efficiency of 92.0±0.36% with a higher 
drug loading content of 36.79±0.17mg. This was because of maximum availability of PCL 
carboxyl groups to entrap the drug. Then, the formulations F8, F9 and F10 has showed % 
entrapment efficiencies of 87.6±1.08%, 82.57±0.78% and 77.78±1.08% with drug loading 
contents of 35.07±0.32mg, 33.02±0.36mg and 31.09±0.33mg respectively. The gradual 
decrease in the % entrapment efficiency then compared to formulation F7 was due to 
increased copolymer concentration because of higher hydrophobic or steric interactions 
between the carboxyl groups of PCL copolymer and drug. 
Hence the F7 formulation has shown highest % entrapment efficiency with higher 
drug loading content when compared with other formulations. So, it was selected as an 
optimized formulation and then it was freeze dried by lyophiliser.  
The entrapment efficiency of lyophilised F7 formulation was found to be 
91.96±0.18% with drug content of 36.76±0.14mg. This signifies that there was no change in 
drug loading content and entrapment efficiency before and after lyophilisation of formulation 
F7.    
 
The results of amount of drug entrapped and percentage entrapment efficiencies of 
Nanoparticle formulations were shown in table no: 16 and17 and graph no: 2 and 3. 
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7.1.2 In vitro Drug release profile of Paclitaxel Nanoparticles 
 
The in vitro drug release studies were performed for the prepared Nanoparticle 
formulations (F1, F2, F3, F4, F5, F6, F7, F8, F9 and F10) and also for optimised freeze dried 
formulation F7. Results were tabulated and graphs were made by plotting cumulative % drug 
release against time in hours on the y axis and x axis respectively. 
The in vitro drug release characteristics for prepared Nanoparticle formulations were 
evaluated with the help of release profiles in graphical plots. 
The formulations F1, F2 and F3 showed a drug release of 35.6%, 42.87% and 50.46% 
at 96 hr respectively. The drug release was increased from F1 to F3, because of the increased 
% entrapment efficiencies due to the availability of increased carboxyl groups of copolymer. 
The formulations F4, F5 and F6 showed a drug release of 66.15%, 73.23% and 
84.77%, at 96 hrs respectively. The percentage drug releases of formulations were increased 
due to increased entrapment efficiencies because of the increased copolymer concentration 
with respect to the drug or due to increase in carboxyl groups of copolymer to entrap the 
drug. 
The formulation F7 has showed a drug release of 89.84% in 96 hours. The release of 
the drug was suddenly increased with a drug loading content of 36.79 mg due to the 
availability of maximum carboxyl groups of copolymer to entrap the drug. Then, the F8, F9 
and F10 have showed a drug release of 83.06%, 79.54% and 78.34% respectively. The 
gradual decrease in drug release when compared with the F7 formulation was found to be due 
increased hydrophobic or steric interactions between drug and carboxyl groups of copolymer 
and also in between the carboxyl groups of copolymers. Hence, the F7 formulation was 
selected as the best formulation with highest percent drug release and also having the higher 
% encapsulation efficiency then compared to the other formulations. 
So, it was selected for the freeze drying to increase the stability during storage. This 
freeze stabilized formulation F7 has showed drug release of 89.82% with a drug loading 
content of 36.76 mg. It was found that there was no significant change in percentage drug 
release for selected formulation F7 before and after lyophilisation. So, it was selected further 
to study the release kinetics. 
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                              Table No: 18 In vitro drug release data of F1 formulation 
  
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 0.87 5.34 5.34 
2. 16 1.23 7.56 7.58 
3. 24 1.89 11.64 11.67 
4. 32 2.41 14.78 14.83 
5. 40            2.99 18.36 18.40 
6. 48 3.50 21.49 21.55 
7. 56 3.88 23.81 23.89 
8. 64 4.42 27.13 27.21 
9. 72 4.91 30.11 30.23 
10. 80 5.27 32.36 32.46 
11. 88 5.52 33.90 34.0 
12. 96 5.78 35.47 35.60 
 
                    
                
            
                     Graph No: 4 In vitro drug release profile of F1 formulation 
                                   Slope = 0.372            Regression = 0.987 
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                   Table No: 19 In vitro drug release data of F2 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8            1.25 7.31 7.31 
2. 16            1.81 10.57 10.60 
3. 24            2.26 13.24 13.25 
4. 32 2.77 16.19 16.24 
5. 40            3.35 19.57 19.64 
6. 48 4.19 24.48 24.57 
7. 56 4.47 26.16 26.23 
8. 64 4.95 28.93 29.04 
9. 72 5.16 30.18 30.28 
10. 80 5.76 33.67 33.79 
11. 88            6.21 36.28 36.44 
12. 96 7.31 42.75 42.87 
 
                      
                    
  
                          Graph No: 5 In vitro drug release profile of F2 formulation 
                                     Slope = 0.397            Regression = 0.985 
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                           Table No: 20 In vitro drug release data of F3 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 1.63 8.12 8.12 
2. 16 2.88 14.34 14.34 
3. 24 3.95 19.67 19.69 
4. 32 4.57 22.72 22.80 
5. 40 5.25 26.12 26.19 
6. 48 6.13 30.48 30.58 
7. 56 6.90 34.29 34.42 
8. 64 7.54 37.47 37.62 
9. 72 8.18 40.64 40.82 
10. 80 8.97 44.57 44.76 
11. 88 9.65 47.98 48.16 
12. 96 10.11 50.24 50.46 
 
                     
                           
                     Graph No: 6 In vitro drug release profile of F3 formulation 
                                     Slope = 0.498            Regression = 0.982 
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                     Table No: 21 In vitro drug release data of F4 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 2.50 9.03 9.03 
2. 16 3.97 14.35 14.36 
3. 24 4.87 17.51 17.63 
4. 32 6.76 24.38 24.46 
5. 40 7.89 28.47 29.67 
6. 48 10.15 36.93 37.08 
7. 56 11.67 42.12 42.26 
8. 64 13.46 48.54 48.74 
9. 72 13.94 50.28 50.51 
10. 80 14.87 54.93 55.07 
11. 88 16.83 60.72 60.96 
12. 96 18.26 65.88 66.15 
 
                 
 
                     Graph No: 7 In vitro drug release profile of F4 formulation 
                                     Slope = 0.674            Regression = 0.992 
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                    Table No: 22 In vitro drug release data of F5 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 2.69 8.95 8.95 
2. 16 3.73 12.43 12.45 
3. 24 4.98 16.58 16.62 
4. 32 7.86 26.17 26.34 
5. 40 9.19 30.58 30.69 
6. 48 11.55 38.42 38.56 
7. 56 14.04 46.71 46.88 
8. 64 16.72 55.63 55.83 
9. 72 17.96 59.75 60.0 
10. 80 19.22 63.94 64.21 
11. 88 20.58 68.46 68.75 
12. 96 21.92 72.91 73.23 
 
                   
                  Graph No: 8 In vitro drug release profile of F5 formulation 
                                   Slope = 0.789            Regression = 0.991 
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                         Table No: 23 In vitro drug release data of F6 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 3.56 10.71 10.71 
2. 16 7.20 15.58 15.60 
3. 24 9.48 21.64 21.69 
4. 32 10.95 28.47 28.57 
5. 40 14.36 32.91 33.02 
6. 48 18.79 43.14 43.28 
7. 56 20.70 56.43 56.64 
8. 64 22.24 62.18 62.44 
9. 72 25.19 66.79 67.06 
10. 80 26.74 75.65 75.97 
11. 88 28.01 80.32 80.67 
12. 96 31.09 84.12 84.77 
 
                  
 
                  Graph No: 9 In vitro drug release profile of F6 formulation 
                                   Slope = 0.911            Regression = 0.991 
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                             Table No: 24 In vitro drug release data of F7 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 4.39 11.95 11.95 
2. 16 6.84 18.61 18.65 
3. 24 9.97 27.12 27.19 
4. 32 13.50 36.71 36.83 
5. 40 14.79 40.21 40.38 
6. 48 17.99 48.91 49.91 
7. 56 19.23 52.29 52.51 
8. 64 23.54 64.01 64.24 
9. 72 26.41 71.79 72.10 
10. 80 29.71 80.78 81.11 
11. 88 30.98 84.21 84.61 
12. 96 32.90 89.43 89.84 
 
                      
 
                  Graph No: 10 In vitro drug release profile of F7 formulation 
                                   Slope = 0.929            Regression = 0.993 
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                         Table No: 25 In vitro drug release data of F8 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 2.87 8.19 8.19 
2. 16 4.91 14.01 14.04 
3. 24 7.79 22.24 22.28 
4. 32 11.27 32.15 32.24 
5. 40 13.31 37.98 38.11 
6. 48 15.47 44.12 44.30 
7. 56 19.41 55.36 55.56 
8. 64 22.15 63.17 63.43 
9. 72 24.71 70.48 70.77 
10. 80 26.43 75.38 75.71 
11. 88 28.09 80.12 80.47 
12. 96 28.99 82.67 83.06 
 
                      
                   
 
                  Graph No: 11 In vitro drug release profile of F8 formulation 
                                   Slope = 0.914            Regression = 0.991 
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                       Table No: 26 In vitro drug release data of F9 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 2.03 6.17 6.17 
2. 16 4.45 13.48 13.50 
3. 24 7.83 23.72 23.78 
4. 32 10.20 30.91 31.01 
5. 40 12.54 37.98 38.13 
6. 48 15.65 47.42 47.58 
7. 56 17.04 51.63 51.84 
8. 64 19.30 58.46 58.70 
9. 72 21.37 64.72 65.01 
10. 80 22.75 68.91 69.22 
11. 88 24.90 75.42 75.75 
12. 96 26.14 79.17 79.54 
 
                 
                   
                    Graph No: 12 In vitro drug release profile of F9 formulation 
                                   Slope = 0.852            Regression = 0.990 
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                  Table No: 27 In vitro drug release data of F10 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 2.91 9.37 9.37 
2. 16 3.87 12.46 12.49 
3. 24 7.06 22.74 22.77 
4. 32 9.16 29.48 29.57 
5. 40 11.79 37.93 38.06 
6. 48 13.96 44.92 45.09 
7. 56 15.58 50.13 50.33 
8. 64 18.02 57.98 58.21 
9. 72 19.45 62.57 62.85 
10. 80 20.74 66.73 67.02 
11. 88 23.31 74.32 75.30 
12. 96 24.24 77.98 78.34 
 
                
                   
                    Graph No: 13 In vitro drug release profile of F10 formulation 
                                    
                                     Slope = 0.829            Regression = 0.992 
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            Table No: 28 In vitro drug release data of Lyophilised F7 formulation 
 
S.No Time (hrs) 
Amount of drug 
release (mg) 
Percentage 
drug release 
Cumulative % 
drug release 
1. 8 4.18 11.35 11.35 
2. 16 6.55 17.79 17.82 
3. 24 10.26 27.86 27.92 
4. 32 13.24 35.94 35.96 
5. 40 15.11 41.0 41.17 
6. 48 17.97 48.76 48.95 
7. 56 19.54 53.02 53.25 
8. 64 23.57 63.97 64.20 
9. 72 26.54 72.01 72.32 
10. 80 29.21 79.25 79.60 
11. 88 31.77 84.19 84.57 
12. 96 32.86 89.40 89.82 
 
                   
                    Graph No: 14 In vitro drug release profile of F10 formulation 
                                    
                                     Slope = 0.924            Regression = 0.993 
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        Table No: 29 Summary of In vitro drug release of Paclitaxel nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Formulation code 
Cumulative % drug release 
at 96 hours 
1. F1 35.60 
2. F2 42.87 
3. F3 50.46 
4. F4 66.15 
5. F5 73.23 
6. F6 84.77 
7. F7 89.84 
8. F8 83.06 
9. F9 79.54 
10.   F10 78.34 
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      Graph No:15 Summarised Invitro drug release profiles of all Paclitaxel nanoparticle 
      formulations 
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7.1.3 RELEASE KINETICS 
 
The release kinetics was studied for an optimised freeze dried F7 formulation by plotting the 
graphs for different kinetic models by using the in vitro drug release data. 
 
a) Zero Order Plot: 
 
      
              Table No: 30 Zero-Order Kinetics plot data for an optimized freeze dried F7
                                 formulation   
 
 
Time (hrs) Cumulative % drug release 
8 11.35 
16 17.82 
24 27.92 
32 35.96 
40 41.17 
48 48.95 
56 53.25 
64 64.20 
72 72.32 
80 79.60 
88 84.57 
96 89.82 
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             Graph No: 16 Zero-Order release profile for an optimized freeze dried F7 
                                         formulation   
 
 
 
             
 
                                
Zero order release kinetics 
Rate constant k0 0.929 hr-1
R2 0.995 
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b) First Order Plot: 
 
 
        Table No: 31 First-Order Kinetics plot data for an optimized freeze dried F7 
                                formulation   
 
                 
                             
Time (hrs) 
Log remaining Cumulative 
% drug release 
8 1.9476 
16 1.9147 
24 1.8578 
32 1.8064 
40 1.7695 
48 1.7079 
56 1.6697 
64 1.5530 
72 1.4421 
80 1.3096 
88 1.1883 
96 1.0081 
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           Graph No: 17 First-Order release profile for an optimized freeze dried F7 
                                         formulation   
  
     
       
 
 
 
 
                             
 
 
 
 
 
First order release kinetics 
Rate constant kt 0.02hr-1
R2 0.935 
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c) Higuchi Plot: 
 
 
 
 
         Table No: 32 Higuchi Kinetics plot data for an optimized freeze dried F7 
                                formulation   
 
 
                   
                      
                           
    
    
    
    
    
    
    
    
    
    
    
    
    
            
            
            
             
SQRT of time 
(hrs) 
Cumulative % drug 
release 
2.828 11.35 
4.0 17.82 
4.898 27.92 
5.656 35.96 
6.324 41.17 
6.928 48.95 
7.483 53.25 
8.0 64.20 
8.485 72.32 
8.944 79.60 
          9.380 84.57 
9,797 89.82 
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              Graph No: 18 Higuchi release profile for an optimized freeze dried F7 
                                     formulation   
 
 
       
 
 
                             
    
    
            
            
    
 
 
 
 
 
Higuchi release kinetics 
R2 0.987 
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d) Korsmeyer – Peppas model kinetics plot: 
 
 
 
Table No: 33 Korsmeyer- Peppas kinetics plot data for an optimized freeze dried F7 
                                formulation   
 
 
 
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Log time (hrs) Log cumulative % drug release 
0.9030 1.0549 
1.2041 1.2509 
1.3802 1.5549 
1.5051 1.5558 
1.6020 1.6145 
1.6812 1.6897 
1.7481 1.7263 
1.8061 1.8075 
1.8573 1.8952 
1.9030 1.9009 
1.9444 1.9272 
1.9822 1.9535 
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    Graph No: 19 Korsmeyer-Peppas release profile for an optimized freeze dried F7 
                               formulation   
 
 
 
        
 
 
                              
 
 
 
 
 
 
 
 
 
 
Korsmeyer-peppas model release kinetics 
R2 n value
0.992 0.408 
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Zero order plot: 
                Zero order plot of a freeze dried formulation F7 was found to be linear with a 
regression value of 0.995, which signifies that the drug was released in a controlled manner 
from the nanoparticles during the release study.  
 
First order plot:     
             The first order plot was made by plotting log remaining cumulative % drug release 
against time and the regression value was found to be 0.935 which indicates that drug release 
was not followed the first order rate kinetics.  
 
Higuchi plot: 
         Higuchi plot was found to be of linear with a regression value of 0.987, which indicates 
that diffusion was one of the mechanisms of the drug release from Nanoparticle matrices. 
 
Korsmeyer-Peppas plot: 
           
The type of invitro mechanism of drug release was best explained by Korsmeyer- Peppas 
plot. The plot was found to be linear with R2  value 0.992 and diffusion exponent ‘n’ value 
was 0.408, According to Korsmeyer-pepps equation, mechanism of drug release based on ‘n’ 
(given in the table no: 4), which indicates that mechanism of drug release from copolymer 
matrices was followed Fickian diffusion.   
 
So, the kinetic studies of an optimized freeze dried F7 formulation with different kinetic 
models has showed that the Paclitaxel release profile was best fitted with zero order plot and 
release mechanism was found to be Fickian diffusion based on ‘n’ value from Korsmeyer-
Peppas plot.  
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7.2 Physical characterization: 
     
          The Paclitaxel loaded MPEG-b-PCL Nanoparticle formulation before and after the 
lyophilisation was subjected to study particle size analysis, Zeta potential and poly dispersive 
index (PDI) by using Malvern instruments, Zetasizer ver. 6.01and surface morphology by 
Scanning electron microscopy (field instruments). 
The results were shown in the Table No: 34, Reports 1, 2, 3, 4, 5, 6 and figures 2, 3. 
 
Table No: 34 Physicochemical characteristics of an optimised Paclitaxel Nanoparticle
                 formulation before and after Lyophilisation  
 
S.No. 
Formulation   
F7 
Average particle Size 
(nm) 
Zeta potential 
(mV) 
Poly dispersive 
Index 
  1. Before 
Lyophilization 
169.7 - 19.6 0.195 
  2. After 
Lyophilization 
187.0 - 15.9 0.170 
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        Report No: 1 Particle size distribution of formulation F7 before lyophilisation. 
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    Report No: 2 Particle size distribution of formulation F7 before lyophilisation. 
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Report No: 3 Zeta potential of an optimised formulation F7 before lyophilisation. 
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       Report No: 4 Particle size distribution of formulation F7 after lyophilisation. 
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Report No: 5 Particle size distribution of formulation F7 after lyophilisation. 
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         Report No: 6 Zeta potential of an optimised formulation F7 after lyophilisation. 
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        SCANNING ELECTRON MICROSCOPY 
 
                    
                   
 
Fig No: 2 SEM photograph of Nanoparticle formulation F7 before Lyophilisation 
 
 
                    
 
       Fig No: 2 SEM photograph of Nanoparticle formulation F7 after Lyophilisation 
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7.2.1 Particle size: 
The average particle size of the nanoparticle formulation F7, before and after lyophilisation 
was found to 169.7 nm and 187.0 nm respectively. The observed particle sizes were fall in 
the range of nano micellar level (10 nm-200 nm) and also the calculated ratio value of 
nanoparticle size before and after lyophilisation was nearer to the value of one which was an 
important indication of conservation of the nanoparticle size after the freeze drying. The 
results were shown in table no: 34 and reports: 1, 3. 
 
7.2.2 Zeta potential:  
The zeta potential values of the formulation F7, before and after freeze drying were -19.6 mV 
and -15.9 mV respectively. The decrease in the zeta potential was due to the effect of PEG in 
the outer shell of nanoparticles and also probably due to the adsorption of Paclitaxel on the 
nanoparticle surfaces during preparation process. The lower negative zeta potential results in 
a reduction of cell repulsion to the nanoparticles up to a certain degree and also contributes to 
the stability of nanosuspension. The results were shown in reports: 2, 4. 
 
7.2.3 Scanning Electron Microscopy:  
The SEM photographs of F7 formulation before and after freeze drying showed that, the 
colloidal nanoparticles before the freeze drying have a spherical shape with nanometer size 
range and smooth surfaces without any noticeable cracks or pin holes. The SEM image of 
after lyophilisation has shown matted like appearance or adhesion between the nanoparticles, 
this was because of lyoprotectant PVA around the nanoparticles.     
 
7.2.4 Poly Dispersity index:  
Poly dispersity index (PDI) values for the formulation F7, before and after lyophilisation 
were found to be 0.195 and 0.17. This lower PDI values indicates that the Nanoparticle 
formulation before and after freeze drying has mono dispersive characteristics and narrow 
particle size distribution. The results were shown in reports: 3, 5. 
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7.3 STABILITY STUDIES OF PACLITAXEL NANOPARTICLES:  
 
The stability studies for an optimised freeze dried formulation F7 was carried for 3 months. 
The evaluation of nanoparticles was carried out by testing Entrapment Efiiciency (%) and in 
vitro drug release in a interval of one month duration. The results of the tests were tabulated 
in the below table 
            
               Table No 35: Summarised stability studies for Freeze dried F7 formulation 
 
 
S.No Storage condition 
Test 
parameters 
1st month 2nd month 3rd month 
1. 50C (Refrigerator) 
Entrapment 
efficiency (%)  
 
In vitro drug 
release (%)  
   
91.70% 
 
 
  89.52% 
91.60% 
 
 
88.98% 
 
89.97% 
 
 
87.89% 
 
2. 
250C/65% RH 
(Room temperature) 
Entrapment 
Efficiency (%) 
 
In vitro drug 
release (%) 
 
91.32% 
 
 
    
  89.68% 
 
89.67% 
 
 
 
87.42% 
86.55% 
 
 
 
86.38% 
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Table No: 36 Summarised stability study data of optimized freeze dried F7 formulation
     for 3 months at 50C  
                                         
 
 
 
    
 
S.No Time (hrs) 
                                   Cumulative % drug release 
Initial 1st Month 2nd Month 3rd Month 
1. 8 11.35 9.47 10.01 9.82 
2. 16 17.82 18.15 19.31 18.39 
3. 24 27.92 27.10 25.96 25.85 
4. 32 35.96 34.99 33.83 33.28 
5. 40 41.17 43.08 42.03 42.24 
6. 48 48.95 46.95 46.30 46.29 
7. 56 53.25 54.30 53.80 54.89 
8. 64 64.20 62.13 61.10 61.69 
9. 72 72.32 72.94 71.86 71.23 
10. 80 79.60 80.52 80.24 78.50 
11. 88 84.57 85.45 85.30 84.02 
12. 96 89.82 89.52 88.98 87.89 
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             Graph No: 20 Comparison of in vitro release profiles at 50C for 3 months 
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Table No: 37 Summarised stability study data of optimized freeze dried F7 formulation
     for 3 months at 250C/65% RH                                          
 
 
 
 
 
 
 
S.No Time (hrs) 
                                   Cumulative % drug release 
Initial 1st Month 2nd Month 3rd Month 
1. 8 11.35 10.23 10.58 9.02 
2. 16 17.82 16.62 16.58 14.94 
3. 24 27.92 27.81 26.92 20.24 
4. 32 35.96 35.83 36.34 27.81 
5. 40 41.17 42.08 40.93 33.12 
6. 48 48.95 49.40 49.35 43.43 
7. 56 53.25 54.28 57.95 56.91 
8. 64 64.20 64.24 65.44 62.70 
9. 72 72.32 72.34 73.75 67.35 
10. 80 79.60 79.61 78.67 76.30 
11. 88 84.57 84.57 83.77 82.09 
12. 96 89.82 89.68 87.42 86.38 
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      Graph No: 21 Comparison of in vitro release profiles at 250C/ 65% RH for 3 months 
 
 
The results of the stability studies of the prepared Paclitaxel nanoparticles, reveals 
that the freeze dried formulation was stable in the refrigerated condition for a period of 3 
months. The entrapment efficiency and drug release of the formulation at 50C did not showed 
any significant change during storage condition when compared with the same formulations 
stored at 250C/ 65% RH which has shown significant changes. 
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                                                                    8. CONCLUSION 
 
The present work entitled, “Development and characterisation of an Antimicrotubular Taxane 
loaded MPEG-b-PCL Nanoparticles” was aimed to develop a nanoparticulate drug delivery 
system of an anticancer drug Paclitaxel using a biodegradable amphiphilic diblock MPEG-b-
PCL copolymer. 
 
The main objective of the work was to develop a controlled release dosage form of Paclitaxel 
nanoparticles for reducing severe side effects associated with conventional delivery system 
like paclitaxel injection(Taxol), because of the low solubility of paclitaxel in water, it was 
first dissolved in Cremophore EL (polyethoxylated castor oil) and Ethanol  and then 
administered, use of this solvent mixture cause serious side effects like sever hypersensitivity 
reactions, neurotoxicity, nephrotoxicity and hypotensive reactions on iv administration. So, 
the inclusion of Paclitaxel in nanoparticle formulations has proved to be a good approach to 
eliminate effects of Cremophore EL and Ethanol. 
The preformulation studies were performed by using infrared spectroscopy, the obtained 
spectra revealed the absence of molecular interactions between the Paclitaxel, MPEG-b-PCL 
copolymer and PVA used in the formulation. 
The Paclitaxel loaded nanoparticles were prepared by Emulsion solvent evaporation 
technique. The formulations containing drug: polymer in various proportions like 1: 3.5, 1: 4, 
1:4.5, 1:5, 1:5.5, 1: 6, 1:6.5, 1:7, 1:7.5 and 1:8 were made and subjected to entrapment 
efficiency and in vitro dissolution studies. The results were indicated that formulation F7 
containing drug: polymer in the ratio of 1:6.5 possessed an entrapment efficiency of 92% and 
a drug release of 89.84% and thereby considered to be the best formulation.  
 
The optimized formulation F7 was lyophilized by freeze dryer to increase the stability of 
nanoparticle formulation during storage. It was further evaluated for % EE and drug release; 
the results showed that there was no significant change in EE% and in vitro drug release 
profile when compared with unlyophilised F7 formulation. 
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The release kinetics of an optimised lyophilised formulation showed zero order drug release 
and followed Fickian diffusion when applied to the Korsmeyer-peppas model for mechanism 
of drug release from copolymer matrices.   
   
The particle sizes of the optimised Nanoparticle formulation F7 before and after 
lyophilisation were found to be in the size range of nanomicelles (10nm-200 nm) and the 
lower negative zeta potential values contributes to reduction of cell repulsion to the 
nanoparticles up to a certain degree and also stabilizes nanosuspension. 
Stability testing of optimised freeze dried formulation F7 at 50 C and 250C/65 % RH for 3 
months showed that formulation was remained stable only at 40 C throughout the study 
period. So, the storage condition proposed for the prepared paclitaxel Nanoparticle 
formulation was refrigerated (50C) condition. 
 
      
 
 
 
 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
                                                     9. BIBLIOGRAPHY 
 
1. Yie. W. Chein., Novel drug delivery systems, Marcel Dekker Inc, Newyork, 1992, 2nd 
edition, 1-2. 
 
2. Jain NK., Targeted delivery of drugs, Advances in the controlled and novel drug delivery, 
CBS publishers, New Delhi, 2001,1st edition, 452. 
 
3. Vyas SP, Khar RK., Targeted and controlled drug delivery, CBS publishers, Delhi, 2002, 
1st edition, 38-79, 219-373. 
 
4. Gupta Manish, Sharma vimukta., Targeted drug delivery systems: A review, Research 
Journal of chemical sciences, 2011, 1, 1-4. 
 
5. Rajesh Singh, James W. Lillard Jr., Nanoparticle-based targeted drug delivery, 
Experimental and Molecular Pathology, 2009, 86, 215–223. 
 
6. Krishna R.S.M, H.G. Shivakumar, D.V. Gowda, S. Banerjee., Nanoparticles: A novel 
colloidal drug delivery system, Indian J. Pharm. Educ. Res, 2006, 40 (1), 15-21. 
 
7. V J Mohanraj , Y Chen., Nanoparticles- A Review, Trop J Pharm Res, 2006, 5 (1), 561-
573. 
 
8. Vivek Kumar Gupta, P.K. kumar, S.Ramesh and Alok Gupta., Nanoparticle Formulation 
for hydrophilic and hydrophobic drugs, Int. J. Res. Pharm. Sci, 2010, 1, 163-169. 
 
9. Libo Wu, Jian Zhang, Wiwik Watanable., Physical and chemical stability of drug 
nanoparticles, Advanced drug delivery reviews, 2011, 1-14. 
 
10. Wassim Abdul Wahed, Ghania degobert, Serge Stainmesse., Freeze-drying nanoparticles: 
Formulation, process and storage considerations, Advanced Drug Delivery Review, 2006; 
58, 1688-1713. 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
 
11. Chengjun Chen, Dandan Han, Cuifang Cai, Xing Tang., An overview of liposome 
lyophilization and its future potential, Journal of Controlled Release, 2010, 142, 299–
311. 
 
12. Matteo Conti, Valeria Tazzari, Cesare Baccini, Ugo De Giorgi., Anticancer drug delivery 
with Nanoparticles, Journal of in vivo, 2006, 20, 697-702. 
 
13. Erikk Ruoslahti, Sangeeta N. Bhatia, Michael J. Sailor., Targeting of drugs and 
nanoparticles to tumors, Journal of cell biology, 2010, 188, 759-768. 
 
14. Irene Brigger, Catherine Dubernet, Patrick Convreur., Nanoparticles in cancertherapy and 
diagnosis, Advanced drug delivery Review, 2002, 54, 631-651. 
 
15. Murali M Yallapu, Menne Jaggi, Subhash C Chawan., Scope of nanotechnology in 
ovarian cancer therapeutics, Journal of Ovarian research, 2010, 15-60. 
 
16. K.K Jain MD., Targeted drug delivery for cancer, Technology in cancer research and 
treatment, 2005, 4, 1-4. 
 
17. Genevieve Gaucher, Robert H. Marchessault, Jean Christophe Leroux., Polyester based 
micelles and nanoparticles for the parentral delivery of taxanes, Journal of controlled 
release, 2010, 143, 2-12. 
 
18. Chaoling He, Sung Wan Kim, Doo Sung Lee., In situ gelling stimuli sensitive copolymer 
hydrogels for drug delivery, Journal of controlled release, 2008, 127, 189-207. 
 
19. Avnesh Kumari, Sudesh Kumar Yadav, Subhash C. Yadav., Biodegradable polymeric 
nanoparticles based drug delivery systems. Journal of Colloids and Surfaces 
Biointerfaces. 2010; 75: 1–18. 
 
20. Kevin Letchford, Richard Liggins, Kishor M. Wasan, Helen Burt., In vitro human plasma 
distribution of nanoparticulate Paclitaxel is dependent on the physicochemical properties 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
of poly (ethylene glycol)-block-poly (caprolactone) nanoparticles, European journal of 
pharmaceutics and biopharmaceutics, 2009, 71, 196-206. 
 
21. T.Musumeci, L.vicari, C.A. Ventura, M.Gulisano, R.Pignatello,  G.puglisi., Lyoprotected 
nanosphere Formulations for Paclitaxel Controlled Delivery, Journal of nanoscience and 
nanotechnology, 2006, 6, 1-8. 
 
22. Honliang Xin, Liangcen Chen, Jijin Gu, Zhangwei, Xiaoling Fang., Enhanced Anti-
glioblastoma efficacy by PTX-loaded PEGylated poly(e-Caprolactone) Nanoparticle: In 
vitro and In vivo evaluation, International journal of Pharmaceutics, 2010, 402, 238-247. 
 
23. Xiaowei Dong, Cynthia A. Mattingly, Michael Tseng, Moo Cho, Russell J. Mumper., 
Development of new lipid based Paclitaxel nanoparticles using sequential simplex 
optimization, European journal of pharmaceutics and biopharmaceutics, 2009, 72, 9-17. 
 
24. Fang Li, Jianing Li, Xuejun Wen, Shenghu Zhou, Xiaowen Tong, Pingping Su, Hong Li, 
Donglushi., Anti-tumor activity of Paclitaxel-loaded Chitosan nanoparticles: An in vitro 
study, Materials science and engineering, 2009, 1-6. 
 
25. Soo Young Lee, Hoon Hyun, Ju Young Youn, Bong Lee, Hai Bang Lee., Preparation on 
nano emulsified Paclitaxel using MPEG-PLGA diblock copolymers, Journal of colloids 
and surfaces, 2008, 126-130. 
 
26. Rajat Sharma, Mohd yasir, Sanjay Bhaskar, Mohd Asif., Formulation and evaluation of 
Paclitaxel loaded PSA-PEG Nanoparticles Journal of Applied pharmaceutical Science, 
2011, 01, 96-98. 
 
27. S Kollipara, G. Bende, R.N. Saha., Rapid and sensitive Liquid chromatography method 
for determination of Paclitaxel from paranteral formulation, nanoparticles, Indian journal 
of Pharmaceutical Sciences, 2010, 72(4), 465-470. 
 
28. T.S. Renuga Devi, S. Gayathri., FTIR and FT-Raman spectral analysis of Paclitaxel 
drugs, Int. journal of pharmaceutical science review and research,2010, 2(2), 106-110. 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
 
29. L.Mu, SS.Feng., A novel Controlled release Formulation for the anticancer drug 
Paclitaxel: PLGA Nanoparticles containing TPGS, Journal of controlled release. 2009, 
86, 33-48. 
 
30. W.J.Trickler, A.A. Nagvekar, A.k Dash., A novel nanoparticle formulation for sustained 
Paclitaxel Delivery, PharmaSciTech, 2008, 9(2), 489-493. 
 
31. Fabianne danhier, Nathalie Lecouturier, Benoit Vroman and Olivier Feron. Paclitaxel-
loaded PEGylated PLGA based nanoparticles: In Vitro and In Vivo Evaluation, Journal 
of Controlled release, 2009, 13, 11-17. 
 
32. Pei Kan, Zhi-Beng Chen, Chau-Jen Lee, I-Ming Chu., Development of nonionic 
surfactant phospholipid o/w emulsion as a Paclitaxel delivery system, Journal of 
Controlled Release, 1999, 58, 271–278. 
 
33. Yonglu wang, Xueming Li, Liyaowang, Ping Wel., Formulation and pharmacokinetic 
evaluation of a Paclitaxel nanosuspension for intravenous delivery, International journal 
of nanomedicine, 2011, 6, 1497-1507. 
 
34. Eui-Joon Cha, Ju Eun Kim, Cheol-He., Stabilized polymeric micelles by electrostatic 
interactions for drug delivery system, EuropeanJournal of Pharmaceutical Sciences, 
2009, 38, 341–346. 
 
35. Mika Pulkkinen, Jere Pikkaraine, Thomas Wirt, Tommy Tarvainen,Vesa Haapa-aho, 
Harri Korhonen, Jukka Seppa, Kristiina Jarvinen., Three-step tumor targeting of 
Paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: 
Formulation development and in vitro anticancer activity, European Journal of 
Pharmaceutics and Biopharmaceutics, 2008, 76, 66–74. 
 
36. Michael C. Cochran, John Eisenbreya, Richard O.Ouma, Michael Soulen,Margaret A. 
Wheat., Doxorubicin and Paclitaxel loaded microbubbles for ultrasound triggered drug  
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
        delivery, International Journal of Pharmaceutics, 2011, 141, 161– 170. 
 
37. Onkar V Khullar, Aaron P Griest, Jon V Frangioni., Nanoparticle migration and delivery 
of Paclitaxel to regional Lymph Nodes in a large animal model, Journal of medicine, 
2011, 1-10. 
 
38. Chi-Yu Huanga, Chih-Ming Chen, Yu-Der Lee., Synthesis of high loading and 
encapsulation efficient Paclitaxel-loaded poly (n-butyl cyanoacrylate) nanoparticles via 
miniemulsion, International Journal of Pharmaceutics, 2007, 338, 267–275. 
 
39. Jin Oh You, Debra T. Auguste., Feedback-regulated Paclitaxel delivery based on poly 
(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles,  
Biomaterials, 2008, 29, 1950-1957. 
 
40. B.B. Lundberg., Preparation and characterization of polymeric pH-sensitive stealth 
nanoparticles for tumor delivery of a lipophilic prodrug of Paclitaxel, International 
Journal of Pharmaceutics, 2011, 408, 208–212. 
 
41. You Ling, Yueshan Huang., Preparation and release efficiency of poly (lactic-co-
glycolic) acid nanoparticles for drug loaded Paclitaxel, IFMBE proceedings, 2008, 19, 
514-517.   
 
42. John K. Jackson, Tawny Hung, Kevin Letchford, Helen M. Burt. The characterization of 
Paclitaxel-loaded microspheres manufactured from blends of PLGA and low molecular 
weight diblock copolymers, International Journal of Pharmaceutics, 2007, 342, 6–17. 
 
43. Sudhir S. Chakravarthi, Sinjan De, Donald W. Miller, Robinson., Comparison of anti-
tumor efficacy of Paclitaxel delivered in Nano-Microparticles, International Journal of 
Pharmaceutics, 2010, 383, 37–44. 
 
44. Roberta Cavalli, Otto Caputo, Maria Rosa Gasco., Preparation and characterization of 
solid lipid nanospheres containing Paclitaxel, European Journal of Pharmaceutical 
Sciences, 2000, 10, 305–309. 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
 
45. Yong Woo Cho, Jaehwi Lee, Sang Cheon Lee, Kang Moo Huh, Kinam Park., 
Hydrotropic agents for study of in vitro Paclitaxel release from polymeric micelles, 
Journal of Controlled Release, 2004, 97, 249– 257. 
 
46. Yogesh Patil, Tanmoy Sadhukha, Linan Ma, Jayanth Panyam., Nanoparticle-mediated 
simultaneous and targeted delivery of Paclitaxel and Tariquidar overcomes tumor drug 
resistance, Journal of Controlled Release, 2009, 136, 21–29. 
 
47. Jae Sung Lee, Su Jung Hwang, Doo Sung Lee., Formulation of Poly (Ethylene Glycol)-b-
poly(caprolactone)  Nanoparticles  via  Nanoprecipitation, Macromolecular research, 
2009, 17(2), 72-78. 
 
48. Mohammed Reza Nabid, Seyed Jamal Tabatabael Rezaei, Roya Sedghi, Hassan 
Nikknejad, Ali Akbar Entezami, Hossein Oskooie, Majid M. Heravi., Self assembeled 
micelles of well defined pentaerythritol centered amphiphilic A4B8 star block copolymers 
based on PCL and PEG for hydrophobic drug delivery, journal of polymer, 2011, 52, 
2799-2809. 
 
49. Yodthong Baimark., Surfactant-free Nanospheres of Methoxy Poly(Ethylene Glycol)-b-
polycaprolactone for controlled release of Ibuprofen, Journal of applied Sciences, 2009, 
9(12), 2287-2293. 
 
50. Xintao Shaui, Hua Ai, Norased Nasongkla, Jinming Gao., Micellar carriers based on 
block copolymers of Poly(e-Caprolactone) and Poly(Ethylene glycol) for Doxorubicin 
delivery, Journal of controlled release, 2004, 98, 425-426. 
 
51. Weihui Xie, Weipu Zhu, Zhiquan Shen., Synthesis, isothermal crystallation and 
micellization of mPEG-PCL diblock copolymers catalysed by yttrium complex, journal 
of polymer, 2007, 48, 6791-6798. 
 
52. Pengwei Dong, Xuihong Wang, Feng Luo, ZhiYong., Self assembeled biodegradable 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
micelles based on star shaped PCL-b-PEG copolymers for chemotherapeutic drug 
delivery, journal of colloids and surfaces, 2010, 358, 128-134. 
 
53. A. Sosnik, D.Cohn., Poly(ethylene glycol)-poly(caprolactone) block oligomers as 
injectable materials. Jorunal of polymer, 2003, 44, 7033-7042. 
 
54. Donghui Zheng, Xiaolinli, Huae Xu, Xiaowei Lu, Yong Hu, Weixin Fan., Study on 
Docetaxel-loaded nanoparticles with high Antitumour efficacy against malignant 
melanoma, ActaBiochim Sin, 2009, 41(7), 578-586. 
 
55. May P.Xiong, Jaine A. Yanez, Neal M. Davies, M. Laird Forrest., Formulation of a 
Geldanamycin Prodrug in MPEG-b-PCL micelles greatly enhances tolerability and 
pharmacokinetics in rats, Journal of Controlled Release, 2008, 129, 33-40. 
 
56. Sa-Won Lee, Min-Hyuk Yun, Seung Wei Jeong, Chemg-Hoon LN, Ji-Young Kim, Msun-
ok Kim., Development of Docetaxel-loaded intravenous formulation, Nanoxel-PM using 
polymer based delivery system, Journal of Controlled Release, 2011, 155(2), 262-271. 
 
57. Maria Teresa Peracchia, Ruxandra Gref , Yoshiharu Minamitake , Avi Domb ,Noah 
Lotan, Robert Langer., PEG-coated nanospheres from amphiphilic diblock and 
multiblock copolymers: Investigation of their drug encapsulation and release 
characteristics, Journal of Controlled Release, 1997, 46, 223–231. 
 
58. Luisanna Ostacolo, Monica Marra, Francesca Ungaro, Silvia Zappavigna, Giovanni 
maglio., Invitro Anticancer activity of Docetaxel-loaded micelles based on PEO-PCL 
block copolymers, Journal of controlled release, 2010, 148, 255-263. 
 
59. Junko Matsumoto,Yuichiro Nakada, Kazuo Sakurai, Tomomi Nakamura and Yoshiteru 
Jakahashi., Preparation of nanoparticles consisted of poly (L-lactide)-poly(ethylene 
glycol)-poly(L-lactide) and their evaluation in vitro, International Journal of 
Pharmaceutics, 1999, 185, 93-101. 
 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
60. Luis A. Guzman, Vinod Labhasetwar, Cunxion song, YangsooJang, A,Michael Lincoff, 
Robert Levy and  Eric J. Topol., Local Intraluminal Infusion of Biodegradable polymeric 
nanoparticles, A Novel Approach for prolonged Drug Delivery After Balloon 
Angioplasty, American Heart Association Inc, 1996, 94, 1441-1448. 
 
61. Rubiana M. Mainardes and Raul C, Evangelista, PLGA nanoparticles containing 
Praziquantel: effect of formulation variables on size distribution, International journal of 
pharmaceutics, 2005, 290, 137-144. 
 
62. Chang-Gu Keum, Young-Wook Noh, Ji-Ho Lim, Chan-Ju Hwang, Joung-Guk No,  Sang-
chulshin., Practical Preparation procedures for Docetaxel- loaded nanoparticles using 
polylacticacid-co-glycolicacid, International Journal of Nanomedicine, 2011, 6, 2225-
2234. 
 
63. Ganesh GNK, Gowthamarajan, Suresh Kumar, Jawahar, Venkatesh, Manjusha., 
Formulation and evaluation of liposomal drug delivery system for an anticancer drug and 
the study the effect of various stabilizers based on physiochemical and in vitro 
charecterization, International of pharmaceutical research and development, 2011, 3(3), 
27-37. 
 
64. http://www.drugbank.ca/drugs/DB01229/paclitaxel. 
 
65. V Kiran Kumar, N Appala Raju, Namratha Rani,T Satyanarayana., The estimation of 
Paclitaxel in parentrals by RP-HPLC, Asian J. Research Chem, 2009, 2, 90-92. 
 
66. http://dailymed.nlm.nih.gov/dailymed/search.cfm/paclitaxel. 
 
67. Ramesh Panchagnula., Pharmaceutical aspects of Paclitaxel. International Journal of 
Pharmaceutics, 1998, 172, 1–15. 
 
68. Stephan Mielke, Alex Sparreboom, Klaus Mross., Peripheral neuropathy: A persisting 
challenge in Paclitaxel-based regimes, European journal of cancer, 2006, 42, 24-30. 
 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
69. http://en.wikipedia.org/wiki/Paclitaxel 
 
70. Erin R. Gardner, William Dahut, William D. Figg., Quantitative determination of total 
and unbound Paclitaxel in Ambraxane, Journal of Chromatography, 2008, 256, 213–218. 
 
71. Goodman & Gilman., the pharmacological basis of therapeutics, 2006, 11th edition, 51. 
  
72. Neville Davidson., The role of Nab-Paclitaxel in managing metastatic breast cancer: a 
report of three cases, Ejc supplement, 2010, 1, 11-18. 
 
73. Anil K. Singla, Alka Garg, Deepika Aggarwal., Paclitaxel and its formulations, 
International Journal of Pharmaceutics, 2002, 235, 179–192. 
 
74. Susmita Mitra, Amarnath Maithra., Nanoparticulate carriers in drug delivery and 
targeting, Proc. Indian Nat. Sci. Acad, 2002, 68(4), 349-360. 
 
75. Yodthong Baimark, Noiniamsa, Nangnit marakot, yaowalak srisuwan. Preparation and 
morphology study of Biodegradable Chitosan/ Methoxy Poly (Ethylene glycol)-b-Poly(e-
Caprolactone) nanocomposite films. International Journal of Polymer Analysis and 
characterisation, 2007, 12, 451-467. 
 
76. Moon Suk Kim, Kwang Seu Seo, Gilson Khang., Preparation of Poly(Ethylene Glycol)-b-
poly(e-caprolactone) Copolymers and their applications as thermosensitive materials, 
Journal of Biomedical materials Research, 2004, 70, 157-158. 
 
77. Ian Wyman, Gabriel Njikang, Guojun Liu., When emulsification meets self-assembly: 
The role of emulsification in directing block copolymer assembly, Progress in Polymer 
Science. 2011, 36, 1152– 1183. 
 
78. Sungwon kim, Yunzhou shi, Jiyoung Kim, Kinam Park, Ji-Xin Cheng., Overcoming the 
barriers in micellar drug delivery: Loading efficiency, invivo stability and micelle-cell 
interaction, Drug delivery, Informa healthcare, 2010, 7, 49-62. 
 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
79. Yuan-Yuan Diao, Hao-Ying Li, Ying-Hua Fu, Min Han, Yu-Lan Hu., Doxorubicin- 
loaded PEG-PCL Copolymer Micelles enhance cytotoxicity and intracellular 
accumulation of Doxorubicin in Adriamycin resistant tumour cells, International  journal 
of nanomedicine, 2011, 6, 1955-1962. 
 
80. Yuancai Dong, Si-Shen Feng., Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-
PLA) Nanoparticles for the controlled delivery of anticancer drugs, Journal of 
Biomaterials, 2004, 25, 2843-2849.  
 
81. Majeti N.v. Ravikumar. Nano and microparticles as controlled drug delivery devices, 
Journal pharmaceutical sciences, 2000, 3, 234-258. 
 
82. Vladmir P Torchilin., Multifunctional and stimuli sensitive pharmaceutical nanocarriers, 
European Journal of Pharmaceutics, 2009, 71, 431-444. 
 
83. http://en.wikipedia.org/wiki/Polyvinyl_alcohol 
 
84. S. K. Saxena., Polyvinyl alcohol PVA, Chemical and technical assessment report, FAO, 
2004, 1-3. 
 
85. Gang Raun, Si-Shen Feng., Preparation and characterisation of poly(lacticacid)-
poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled 
release of Paclitaxel. Journal of Biomaterials, 2003, 24, 5037-5044. 
 
86. John Coates., Interpretation of IR Spectra, A practical approach, Enclyopedia of 
Analytical Chemistry, 2000, 10815-10837. 
 
87. Y. Kodama, L. D. B. Machado, C. Giovedi, K. Nakayama., FTIR investigation of 
Irradiated biodegradable blends, Nanotechnology Research institute of advanced 
industrial science and technology, Japan, 2006, 15, 8212-8219. 
 
                                                                                  BIBLIOGRAPHY 
 
Dept. of Pharmaceutics, KM college of Pharmacy. Madurai    
 
88. Jagadeesh G Hiremath, V Kusum Devi., Preparation and in vitro characterization of 
Paclitaxel-loaded injectable microspheres, Asian journal of Pharmaceutics, 2010, 4(3), 
205-212. 
  
89. Harris Shoaib M, Jaweria Tazeen., Evalution drug release kinetics from Ibuprofen Matrix 
tablets using HPMC, Journal of Pharmaceutical Sciences, 2006, 19(2), 119-124. 
 
90. Golam Kibria, Reza-Ul-Jalil., The effect of the ratio of two acrylic polymers on the in 
vitro release kinetics of Ketoprofen from pellets prepared by extrusion and spheronisation 
technique, Pak. J. Pharm. Sci, 2008, 21(2), 92-97. 
 
91. Bivash Mandal, Kenneth S. Alexander, Alan T. Riga., Sulfacetamide loaded Eudragit RL 
100 nanosuspension with potential for ocular delivery, Journal of Pharmaceutical 
sciences, 2010, 13(4), 510-523. 
 
92. Stability testing of Active pharmaceutical ingredients and finished pharmaceutical 
products. WHO, 2009, 92. 
